The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research report: Human HPX (hemopexin) functional annotation (UniProt P02790)

Scope and target verification

The target gene/protein is HPX encoding hemopexin, UniProt P02790, in Homo sapiens. The literature retrieved here consistently describes HPX as an extracellular/plasma heme-binding glycoprotein that scavenges free heme and delivers it to cells (notably liver) via receptor-mediated pathways, matching the UniProt description and hemopexin-family role. (li2023doubleedgedfunctionsof pages 1-2, pierro2025trackinghemopexinintracellularly pages 23-25)

1) Key concepts and definitions (current understanding)

1.1. What HPX is

Hemopexin is described as a plasma glycoprotein (~60 kDa) and the highest-affinity heme-binding protein in plasma, functioning as a systemic heme scavenger during hemolysis. (li2023doubleedgedfunctionsof pages 1-2)

1.2. Primary molecular function: heme scavenging and transport

The core biochemical role of HPX is to bind free heme in extracellular fluids and limit heme-mediated oxidative/inflammatory toxicity. HPX is routinely framed as a “second-line” defense in hemolysis when upstream hemoglobin scavenging (e.g., haptoglobin-bound hemoglobin) is saturated/depleted, allowing heme to accumulate and transfer to HPX. (li2023doubleedgedfunctionsof pages 2-3, li2023doubleedgedfunctionsof pages 1-2)

Stoichiometry and physiological abundance. Reviews and mechanistic literature report circulating HPX levels on the order of ~0.4–1.5 mg/mL (or ~0.5–1.5 mg/mL), and note heme binding behavior that is 1:1 at low heme concentrations but can reach ≥2:1 (heme:HPX) at higher heme loads. (li2023doubleedgedfunctionsof pages 1-2, pierro2025trackinghemopexinintracellularly pages 23-25)

1.3. Localization: extracellular fluids with liver-centered clearance

HPX is fundamentally an extracellular protein present in plasma and also reported in cerebrospinal fluid and lymph. Its heme-scavenging role is linked to systemic delivery of heme to the liver, where heme is catabolized and iron handled. (pierro2025trackinghemopexinintracellularly pages 1-2)

1.4. Receptors and uptake pathways (HPX → cell biology)

A canonical mechanism described in recent reviews is CD91/LRP1-mediated endocytosis of heme–HPX (often highlighted for hepatic uptake/clearance). (li2023doubleedgedfunctionsof pages 1-2, li2023doubleedgedfunctionsof pages 2-3)

More recent mechanistic cell-model work extends this view by showing HPX uptake/trafficking can involve additional receptors and pathways:
- LRP1 is reported as a high-affinity HPX-binding protein with Kd ≈ 4 nM. (pierro2025trackinghemopexinintracellularly pages 2-3)
- In human immune/liver cell models, HPX trafficked with transferrin and transferrin receptor 1 (TfR1) in Rab5-positive early endosomes, consistent with clathrin-mediated endocytosis routes used by iron transport machinery; TfR2 co-localization suggests potential contribution to liver targeting. (pierro2025trackinghemopexinintracellularly pages 1-2, pierro2025trackinghemopexinintracellularly pages 6-8)
- Importantly, heme–HPX endocytosis was observed even in LRP1−/− cells, implying uptake routes beyond LRP1 alone. (pierro2025trackinghemopexinintracellularly pages 1-2)

1.5. Downstream biochemical pathway: HO-1/HMOX1 induction and iron handling

Once internalized, heme delivered via HPX is connected to induction of a cytoprotective program, including induction of heme oxygenase-1 (HMOX1/HO-1), ferritin induction, and other antioxidant responses. (pierro2025trackinghemopexinintracellularly pages 1-2, montecinos2019whatisnext pages 1-3)

Reviews also link heme–HPX delivery to transcriptional regulation of HO-1 via relief of Bach1 repression and to broader iron-handling systems (IRP/IRE and ferritin storage). (montecinos2019whatisnext pages 1-3)

2) Recent developments and latest research (prioritize 2023–2024)

2.1. 2023 review synthesis: “double-edged” HPX roles and therapeutic strategies

A 2023 peer-reviewed review (“Double-edged functions of hemopexin in hematological related diseases”) compiles evidence that HPX is frequently depleted/insufficient in hemolysis-driven conditions (e.g., SCD, transfusion-induced hemolysis, sepsis), motivating HPX supplementation and related approaches, while also noting potential deleterious effects in some contexts. The review summarizes translational strategies including recombinant production, modification/enhancement, combined scavenger strategies, and gene-therapy concepts. (li2023doubleedgedfunctionsof pages 1-2, li2023doubleedgedfunctionsof pages 9-10)

The same review cites diverse disease associations of HPX levels (e.g., sepsis outcomes, malaria severity relationships, CNS hemorrhage contexts) and notes a phase 1 clinical trial mention in sickle cell anemia (NCT04285827, as cited within the review). (li2023doubleedgedfunctionsof pages 8-9)

2.2. 2024 review: targeting excess heme (and by extension HPX depletion) in SCD-related priapism

A 2024 review on priapism in sickle cell disease emphasizes that intravascular hemolysis in SCD can reduce haptoglobin and hemopexin levels, contributing to accumulation of free hemoglobin/heme and downstream inflammatory signaling. The review frames reducing excess free heme as a therapeutic concept relevant to priapism pathophysiology. (silveira2024targetinghemein pages 2-3)

2.3. 2024 primary human cohort: burns/trauma show heme elevation with scavenger depletion; prognostic associations

A 2024 Frontiers in Immunology primary study measured plasma heme and scavengers (including hemopexin) in large cohorts of injured patients:
- 98 burn patients and 147 trauma patients sampled at ultra-early and acute timepoints (≤1 hour and 4–72 hours post injury). (tullie2024severethermaland pages 1-2)
- The study reports that elevated plasma heme in burns/trauma coincided with reduced hemopexin and albumin (and other scavengers), consistent with a stressed heme-scavenging system. (tullie2024severethermaland pages 1-2, tullie2024severethermaland pages 15-16)

In burns, day-1 total heme was associated with both sepsis and mortality risk; notably, a 6.5 µM higher day-1 heme corresponded to increased odds of sepsis and mortality in logistic models (details in Section 5). (tullie2024severethermaland pages 10-11)

Figure evidence for these dynamics (heme over time; scavenger protein trajectories including hemopexin) is available in the study’s panels (Figures 3 and 5). (tullie2024severethermaland media 71c61103)

2.4. 2024 plasma proteomics + machine learning: HPX differentiates two descending thoracic aortic disease phenotypes

A 2024 Clinical Proteomics study compared plasma proteomes in descending type B dissection (n=75) versus descending thoracic aortic aneurysm (DTAA; n=62) and found that HPX was the only protein significantly different at stringent multiple-testing thresholds. (momenzadeh2024differentiationbetweendescending pages 1-2, momenzadeh2024differentiationbetweendescending pages 5-7)

The same study used machine learning and ranked HPX among top features (permutation importance) and reported held-out performance metrics (precision–recall AUC around 0.7). (momenzadeh2024differentiationbetweendescending pages 1-2, momenzadeh2024differentiationbetweendescending pages 5-7)

3) Current applications and real-world implementations

3.1. HPX as a biomarker in hemolysis-driven states

Across hemolytic/inflammatory diseases, HPX is often discussed as a candidate biomarker of heme-scavenging capacity and disease stage/severity. In pediatric SCD biomarker profiling (Ghana; 2021–2022), HPX was included in a multiplex panel of “heme scavengers” (HO-1, HPX, haptoglobin) and correlated with hematologic parameters; the study also describes ROC/AUC analyses to support predictive algorithms, although numeric HPX values/AUCs were not extractable from the retrieved excerpt. (lekpor2024circulatingbiomarkersassociated pages 1-2)

In vascular disease proteomics (type B dissection vs DTAA), HPX emerged as the key differentiating protein after multiple-testing correction, demonstrating its practical appearance in real-world clinical proteomics pipelines for difficult-to-separate phenotypes. (momenzadeh2024differentiationbetweendescending pages 1-2, momenzadeh2024differentiationbetweendescending pages 7-9)

3.2. HPX-centered therapeutic concepts (translation in progress)

Recent reviews emphasize restoration of heme scavenging as a therapeutic direction when endogenous HPX is depleted. Strategies discussed include HPX supplementation, combined Hb/heme scavenger approaches (Hp+HPX), recombinant HPX production, fusion proteins, and viral gene delivery concepts (e.g., AAV-mediated sustained expression) as preclinical-to-translational approaches. (li2023doubleedgedfunctionsof pages 9-10, li2023doubleedgedfunctionsof pages 1-2)

4) Expert opinions and analysis (authoritative synthesis)

4.1. HPX as a “cytoprotective” heme-delivery system rather than passive binder

Mechanistic literature frames HPX not only as a heme sink but as a ligand delivery system that initiates regulated cellular responses. Heme–HPX endocytosis is linked to HO-1 induction and coordinated iron handling (ferritin induction, transferrin receptor downregulation), implying HPX participates in heme-responsive homeostatic programming rather than simple neutralization. (pierro2025trackinghemopexinintracellularly pages 1-2, montecinos2019whatisnext pages 1-3)

4.2. Receptor complexity and cell-type specificity is an active area

While CD91/LRP1 is often presented as the canonical uptake route, newer cell work suggests multiple receptors and endocytic routes (TfR1/TfR2 involvement; uptake in LRP1−/− cells), which has implications for tissue targeting, drug design (engineered HPX), and interpretation of HPX behavior in immune versus hepatic settings. (pierro2025trackinghemopexinintracellularly pages 1-2, pierro2025trackinghemopexinintracellularly pages 6-8)

4.3. “Double-edged” interpretation in disease: protective vs context-dependent harms

The 2023 review explicitly cautions that HPX may be protective in many heme-overload contexts yet could have deleterious associations/impacts in certain settings, arguing for context-specific evaluation (e.g., timing, compartment, concurrent hemoglobin/heme loads, organ vulnerability). This is consistent with the broader theme that heme biology and scavenger systems can both buffer toxicity and modulate immune/vascular pathways. (li2023doubleedgedfunctionsof pages 9-10)

5) Relevant statistics and data from recent studies (with context)

5.1. Human burns cohort: heme predicts sepsis and mortality; scavenger depletion shown in figures

In the 2024 burns/trauma cohort study:
- Burns cohort: n=98 enrolled; sepsis assessed in n=79, with 42/79 (53%) developing sepsis. (tullie2024severethermaland pages 10-11)
- A 6.5 µM higher day-1 total heme was associated with:
- Sepsis (unadjusted): OR 1.24 (95% CI 1.05–1.46), p=0.013; adjusted (age, gender, %TBSA): OR 1.12 (0.95–1.33), p=0.172. (tullie2024severethermaland pages 10-11)
- Mortality (unadjusted): OR 1.63 (1.12–2.37), p=0.004; adjusted: OR 1.52 (1.02–2.28), p=0.021. (tullie2024severethermaland pages 10-11)
- Discrimination of survivors vs non-survivors using day-1 heme: AUROC 0.768 (95% CI 0.615–0.922) vs rBAUX AUROC 0.718. (tullie2024severethermaland pages 10-11)

Although numeric plasma hemopexin concentrations were not present in the extracted text snippets, the paper reports hemopexin trajectories and depletion after injury, and the relevant visual evidence is in panels showing hemopexin over time (Figure 5). (tullie2024severethermaland media 71c61103)

5.2. Human descending thoracic aortic disease proteomics: HPX differential expression and ML metrics

In the 2024 Clinical Proteomics study:
- Sample sizes: 75 descending type B dissection vs 62 DTAA (total 137). (momenzadeh2024differentiationbetweendescending pages 1-2, momenzadeh2024differentiationbetweendescending pages 5-7)
- HPX was the only significantly different protein after correction, with Log2FC = −0.25 and B-H adjusted p = 0.0081 (Table 2). (momenzadeh2024differentiationbetweendescending pages 7-9)
- ML performance reported includes a held-out test-set precision–recall AUC ≈ 0.7; additional metrics in extracted text include accuracy 0.74 and F1-score 0.67 for the optimized SVC model. (momenzadeh2024differentiationbetweendescending pages 1-2, momenzadeh2024differentiationbetweendescending pages 5-7)

5.3. Quantitative receptor affinity and physiological concentration ranges

Mechanistic literature reports LRP1 binding Kd ≈ 4 nM for HPX, supporting high-affinity receptor-mediated uptake. (pierro2025trackinghemopexinintracellularly pages 2-3)

Reported plasma concentrations of HPX are ~0.4–1.5 mg/mL (≈15.3 µM average in one synthesis), providing a scale for heme-buffering capacity. (pierro2025trackinghemopexinintracellularly pages 23-25)

Evidence summary table

The following table consolidates HPX functional annotation, pathway placement, and key recent quantitative findings.

Table: This table summarizes the functional annotation of human HPX/hemopexin, emphasizing ligand binding, uptake pathways, intracellular fate, disease relevance, and recent translational findings. It is designed as a compact evidence map for narrative reporting and citation-supported interpretation.

Notes on evidence limitations (important for interpretation)

• Some 2024 studies (e.g., pediatric SCD biomarker profiling) are retrieved here only as partial excerpts; the available text indicates HPX was measured and analyzed (including ROC/AUC discussions), but numerical HPX group means/AUCs were not extractable from the retrieved sections. (lekpor2024circulatingbiomarkersassociated pages 1-2)
• The 2024 burns/trauma study provides strong quantitative evidence for heme burden and shows hemopexin depletion in figures; however, the extracted text snippets did not include the absolute hemopexin concentrations, emphasizing the need to consult full tables/supplements for precise HPX numeric values. (tullie2024severethermaland pages 1-2, tullie2024severethermaland media 71c61103)

Key references (with URLs and publication dates)

• Li Y et al. “Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application.” Frontiers in Immunology (Nov 2023). https://doi.org/10.3389/fimmu.2023.1274333 (li2023doubleedgedfunctionsof pages 1-2, li2023doubleedgedfunctionsof pages 9-10)
• Silveira THR et al. “Targeting heme in sickle cell disease: new perspectives on priapism treatment.” Frontiers in Physiology (Jul 2024). https://doi.org/10.3389/fphys.2024.1435220 (silveira2024targetinghemein pages 2-3)
• Tullie S et al. “Severe thermal and major traumatic injury results in elevated plasma concentrations of total heme …” Frontiers in Immunology (Jun 2024). https://doi.org/10.3389/fimmu.2024.1416820 (tullie2024severethermaland pages 1-2, tullie2024severethermaland pages 10-11, tullie2024severethermaland media 71c61103)
• Momenzadeh A et al. “Differentiation between descending thoracic aortic diseases using machine learning and plasma proteomic signatures.” Clinical Proteomics (Jun 2024). https://doi.org/10.1186/s12014-024-09487-4 (momenzadeh2024differentiationbetweendescending pages 1-2, momenzadeh2024differentiationbetweendescending pages 7-9)
• Lekpor CE et al. “Circulating biomarkers associated with pediatric sickle cell disease.” Frontiers in Molecular Biosciences (Dec 2024). https://doi.org/10.3389/fmolb.2024.1481441 (lekpor2024circulatingbiomarkersassociated pages 1-2)

References

1. (li2023doubleedgedfunctionsof pages 1-2): Yijin Li, Renyu Chen, Chaofan Wang, Jun Deng, and Shanshan Luo. Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application. Frontiers in Immunology, Nov 2023. URL: https://doi.org/10.3389/fimmu.2023.1274333, doi:10.3389/fimmu.2023.1274333. This article has 11 citations and is from a peer-reviewed journal.

2. (pierro2025trackinghemopexinintracellularly pages 23-25): E. Pierro, T. L. Duarte, Hans Bäumler, B. Rose, D. Moore, J. Eskew, R. Vanacore, S. Hartson, Dennis W. Province, D. Skaff, and Ann Smith. Tracking hemopexin intracellularly and defining hemopexin protein “interactomes” in human immune and liver cell models. Frontiers in Physiology, Nov 2025. URL: https://doi.org/10.3389/fphys.2025.1613917, doi:10.3389/fphys.2025.1613917. This article has 0 citations.

3. (li2023doubleedgedfunctionsof pages 2-3): Yijin Li, Renyu Chen, Chaofan Wang, Jun Deng, and Shanshan Luo. Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application. Frontiers in Immunology, Nov 2023. URL: https://doi.org/10.3389/fimmu.2023.1274333, doi:10.3389/fimmu.2023.1274333. This article has 11 citations and is from a peer-reviewed journal.

4. (pierro2025trackinghemopexinintracellularly pages 1-2): E. Pierro, T. L. Duarte, Hans Bäumler, B. Rose, D. Moore, J. Eskew, R. Vanacore, S. Hartson, Dennis W. Province, D. Skaff, and Ann Smith. Tracking hemopexin intracellularly and defining hemopexin protein “interactomes” in human immune and liver cell models. Frontiers in Physiology, Nov 2025. URL: https://doi.org/10.3389/fphys.2025.1613917, doi:10.3389/fphys.2025.1613917. This article has 0 citations.

5. (pierro2025trackinghemopexinintracellularly pages 2-3): E. Pierro, T. L. Duarte, Hans Bäumler, B. Rose, D. Moore, J. Eskew, R. Vanacore, S. Hartson, Dennis W. Province, D. Skaff, and Ann Smith. Tracking hemopexin intracellularly and defining hemopexin protein “interactomes” in human immune and liver cell models. Frontiers in Physiology, Nov 2025. URL: https://doi.org/10.3389/fphys.2025.1613917, doi:10.3389/fphys.2025.1613917. This article has 0 citations.

6. (pierro2025trackinghemopexinintracellularly pages 6-8): E. Pierro, T. L. Duarte, Hans Bäumler, B. Rose, D. Moore, J. Eskew, R. Vanacore, S. Hartson, Dennis W. Province, D. Skaff, and Ann Smith. Tracking hemopexin intracellularly and defining hemopexin protein “interactomes” in human immune and liver cell models. Frontiers in Physiology, Nov 2025. URL: https://doi.org/10.3389/fphys.2025.1613917, doi:10.3389/fphys.2025.1613917. This article has 0 citations.

7. (montecinos2019whatisnext pages 1-3): Luis Montecinos, Jeffrey D. Eskew, and Ann Smith. What is next in this “age” of heme-driven pathology and protection by hemopexin? an update and links with iron †. Pharmaceuticals, 12:144, Sep 2019. URL: https://doi.org/10.3390/ph12040144, doi:10.3390/ph12040144. This article has 33 citations.

8. (li2023doubleedgedfunctionsof pages 9-10): Yijin Li, Renyu Chen, Chaofan Wang, Jun Deng, and Shanshan Luo. Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application. Frontiers in Immunology, Nov 2023. URL: https://doi.org/10.3389/fimmu.2023.1274333, doi:10.3389/fimmu.2023.1274333. This article has 11 citations and is from a peer-reviewed journal.

9. (li2023doubleedgedfunctionsof pages 8-9): Yijin Li, Renyu Chen, Chaofan Wang, Jun Deng, and Shanshan Luo. Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application. Frontiers in Immunology, Nov 2023. URL: https://doi.org/10.3389/fimmu.2023.1274333, doi:10.3389/fimmu.2023.1274333. This article has 11 citations and is from a peer-reviewed journal.

10. (silveira2024targetinghemein pages 2-3): Tammyris Helena Rebecchi Silveira, Fabiano Beraldi Calmasini, Mariana Gonçalves de Oliveira, Fernando Ferreira Costa, and Fábio Henrique Silva. Targeting heme in sickle cell disease: new perspectives on priapism treatment. Frontiers in Physiology, Jul 2024. URL: https://doi.org/10.3389/fphys.2024.1435220, doi:10.3389/fphys.2024.1435220. This article has 9 citations.

11. (tullie2024severethermaland pages 1-2): Sebastian Tullie, Thomas Nicholson, Jonathan R. B. Bishop, Kirsty C. McGee, Ali Asiri, Jack Sullivan, Yung-Yi Chen, Amanda V. Sardeli, Antonio Belli, Paul Harrison, Naiem S. Moiemen, Janet M. Lord, and Jon Hazeldine. Severe thermal and major traumatic injury results in elevated plasma concentrations of total heme that are associated with poor clinical outcomes and systemic immune suppression. Frontiers in Immunology, Jun 2024. URL: https://doi.org/10.3389/fimmu.2024.1416820, doi:10.3389/fimmu.2024.1416820. This article has 15 citations and is from a peer-reviewed journal.

12. (tullie2024severethermaland pages 15-16): Sebastian Tullie, Thomas Nicholson, Jonathan R. B. Bishop, Kirsty C. McGee, Ali Asiri, Jack Sullivan, Yung-Yi Chen, Amanda V. Sardeli, Antonio Belli, Paul Harrison, Naiem S. Moiemen, Janet M. Lord, and Jon Hazeldine. Severe thermal and major traumatic injury results in elevated plasma concentrations of total heme that are associated with poor clinical outcomes and systemic immune suppression. Frontiers in Immunology, Jun 2024. URL: https://doi.org/10.3389/fimmu.2024.1416820, doi:10.3389/fimmu.2024.1416820. This article has 15 citations and is from a peer-reviewed journal.

13. (tullie2024severethermaland pages 10-11): Sebastian Tullie, Thomas Nicholson, Jonathan R. B. Bishop, Kirsty C. McGee, Ali Asiri, Jack Sullivan, Yung-Yi Chen, Amanda V. Sardeli, Antonio Belli, Paul Harrison, Naiem S. Moiemen, Janet M. Lord, and Jon Hazeldine. Severe thermal and major traumatic injury results in elevated plasma concentrations of total heme that are associated with poor clinical outcomes and systemic immune suppression. Frontiers in Immunology, Jun 2024. URL: https://doi.org/10.3389/fimmu.2024.1416820, doi:10.3389/fimmu.2024.1416820. This article has 15 citations and is from a peer-reviewed journal.

14. (tullie2024severethermaland media 71c61103): Sebastian Tullie, Thomas Nicholson, Jonathan R. B. Bishop, Kirsty C. McGee, Ali Asiri, Jack Sullivan, Yung-Yi Chen, Amanda V. Sardeli, Antonio Belli, Paul Harrison, Naiem S. Moiemen, Janet M. Lord, and Jon Hazeldine. Severe thermal and major traumatic injury results in elevated plasma concentrations of total heme that are associated with poor clinical outcomes and systemic immune suppression. Frontiers in Immunology, Jun 2024. URL: https://doi.org/10.3389/fimmu.2024.1416820, doi:10.3389/fimmu.2024.1416820. This article has 15 citations and is from a peer-reviewed journal.

15. (momenzadeh2024differentiationbetweendescending pages 1-2): Amanda Momenzadeh, Simion Kreimer, Dongchuan Guo, Matthew Ayres, Daniel Berman, Kuang-Yuh Chyu, Prediman K. Shah, Dianna Milewicz, Ali Azizzadeh, Jesse G. Meyer, and Sarah Parker. Differentiation between descending thoracic aortic diseases using machine learning and plasma proteomic signatures. Clinical Proteomics, Jun 2024. URL: https://doi.org/10.1186/s12014-024-09487-4, doi:10.1186/s12014-024-09487-4. This article has 2 citations and is from a peer-reviewed journal.

16. (momenzadeh2024differentiationbetweendescending pages 5-7): Amanda Momenzadeh, Simion Kreimer, Dongchuan Guo, Matthew Ayres, Daniel Berman, Kuang-Yuh Chyu, Prediman K. Shah, Dianna Milewicz, Ali Azizzadeh, Jesse G. Meyer, and Sarah Parker. Differentiation between descending thoracic aortic diseases using machine learning and plasma proteomic signatures. Clinical Proteomics, Jun 2024. URL: https://doi.org/10.1186/s12014-024-09487-4, doi:10.1186/s12014-024-09487-4. This article has 2 citations and is from a peer-reviewed journal.

17. (lekpor2024circulatingbiomarkersassociated pages 1-2): Cecilia Elorm Lekpor, Felix Abekah Botchway, Adel Driss, Alaijah Bashi, Afua D. Abrahams, Kwadwo Asamoah Kusi, Godfred Futagbi, Ernest Alema-Mensah, William Agbozo, Wesley Solomon, Adriana Harbuzariu, Andrew A. Adjei, and Jonathan K. Stiles. Circulating biomarkers associated with pediatric sickle cell disease. Frontiers in Molecular Biosciences, Dec 2024. URL: https://doi.org/10.3389/fmolb.2024.1481441, doi:10.3389/fmolb.2024.1481441. This article has 5 citations.

18. (momenzadeh2024differentiationbetweendescending pages 7-9): Amanda Momenzadeh, Simion Kreimer, Dongchuan Guo, Matthew Ayres, Daniel Berman, Kuang-Yuh Chyu, Prediman K. Shah, Dianna Milewicz, Ali Azizzadeh, Jesse G. Meyer, and Sarah Parker. Differentiation between descending thoracic aortic diseases using machine learning and plasma proteomic signatures. Clinical Proteomics, Jun 2024. URL: https://doi.org/10.1186/s12014-024-09487-4, doi:10.1186/s12014-024-09487-4. This article has 2 citations and is from a peer-reviewed journal.

19. (tullie2024severethermaland pages 6-7): Sebastian Tullie, Thomas Nicholson, Jonathan R. B. Bishop, Kirsty C. McGee, Ali Asiri, Jack Sullivan, Yung-Yi Chen, Amanda V. Sardeli, Antonio Belli, Paul Harrison, Naiem S. Moiemen, Janet M. Lord, and Jon Hazeldine. Severe thermal and major traumatic injury results in elevated plasma concentrations of total heme that are associated with poor clinical outcomes and systemic immune suppression. Frontiers in Immunology, Jun 2024. URL: https://doi.org/10.3389/fimmu.2024.1416820, doi:10.3389/fimmu.2024.1416820. This article has 15 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
  

Citations

1. li2023doubleedgedfunctionsof pages 1-2
2. pierro2025trackinghemopexinintracellularly pages 1-2
3. pierro2025trackinghemopexinintracellularly pages 2-3
4. montecinos2019whatisnext pages 1-3
5. li2023doubleedgedfunctionsof pages 8-9
6. silveira2024targetinghemein pages 2-3
7. tullie2024severethermaland pages 1-2
8. tullie2024severethermaland pages 10-11
9. lekpor2024circulatingbiomarkersassociated pages 1-2
10. li2023doubleedgedfunctionsof pages 9-10
11. momenzadeh2024differentiationbetweendescending pages 7-9
12. pierro2025trackinghemopexinintracellularly pages 23-25
13. li2023doubleedgedfunctionsof pages 2-3
14. pierro2025trackinghemopexinintracellularly pages 6-8
15. tullie2024severethermaland pages 15-16
16. momenzadeh2024differentiationbetweendescending pages 1-2
17. momenzadeh2024differentiationbetweendescending pages 5-7
18. tullie2024severethermaland pages 6-7
19. https://doi.org/10.3389/fimmu.2023.1274333
20. https://doi.org/10.3389/fphys.2024.1435220
21. https://doi.org/10.3389/fimmu.2024.1416820
22. https://doi.org/10.1186/s12014-024-09487-4
23. https://doi.org/10.3389/fmolb.2024.1481441
24. https://doi.org/10.3389/fimmu.2023.1274333,
25. https://doi.org/10.3389/fphys.2025.1613917,
26. https://doi.org/10.3390/ph12040144,
27. https://doi.org/10.3389/fphys.2024.1435220,
28. https://doi.org/10.3389/fimmu.2024.1416820,
29. https://doi.org/10.1186/s12014-024-09487-4,
30. https://doi.org/10.3389/fmolb.2024.1481441,

Hemopexin (HPX, P02790) – Structure, Function, and Biological Role in Humans

Introduction: The HPX gene encodes hemopexin, a glycoprotein best known as the human plasma protein with the highest binding affinity for heme (pubmed.ncbi.nlm.nih.gov). Hemopexin is primarily synthesized in the liver and secreted into the bloodstream, where it plays a crucial role in heme scavenging and iron homeostasis (www.frontiersin.org) (www.frontiersin.org). The protein has a molecular weight of ~60 kDa and consists of a single polypeptide chain (439 amino acids) stabilized by multiple disulfide bonds and glycosylation sites (en.wikipedia.org). Structurally, hemopexin is composed of two similar β-propeller domains (each formed by four blade-like repeats) connected by a linker (pubmed.ncbi.nlm.nih.gov). These two domains create a high-affinity heme-binding pocket at their interface, enabling hemopexin to tightly sequester free heme (iron protoporphyrin IX) released during hemolysis or tissue injury (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). Below, we discuss hemopexin’s primary function, the biological processes and pathways it influences, its cellular localization, and recent research insights, with a focus on evidence from current literature.

Primary Function: High-Affinity Heme Scavenging and Transport

Hemopexin’s principal function is to bind free heme with extraordinary affinity and facilitate its safe clearance from the body. Free heme is generated when hemoglobin (from red blood cells) or myoglobin (from muscle) is broken down, especially during intravascular hemolysis or tissue hemorrhage (pubmed.ncbi.nlm.nih.gov). If left unbound, free heme is highly toxic: it catalyzes the formation of reactive oxygen species and free iron ions, triggers inflammation, and can damage cells and organs (www.frontiersin.org). Hemopexin provides a protective sink for this free heme. Each hemopexin molecule binds one heme in a 1:1 complex under normal conditions, and it can bind a second heme at higher concentrations (albeit with lower affinity) (www.frontiersin.org). Notably, hemopexin’s affinity for heme is the highest of any known protein, with binding constants in the sub-nanomolar range (pubmed.ncbi.nlm.nih.gov). This ensures that even very low levels of free heme are scavenged; hemopexin will effectively out-compete other molecules (such as albumin or lipoproteins) for heme binding (www.frontiersin.org). By tightly sequestering heme, hemopexin prevents heme’s pro-oxidant and pro-inflammatory effects, protecting tissues from oxidative damage and averting heme-driven inflammatory signaling (www.frontiersin.org).

Once hemopexin has bound heme, the complex is recognized by specific cell-surface receptors, allowing targeted delivery of heme for degradation. In humans, the low-density lipoprotein receptor-related protein 1 (LRP1), also known as CD91, is the primary receptor that binds the heme–hemopexin complex (pubmed.ncbi.nlm.nih.gov). Hvidberg et al. (2005) identified LRP1/CD91 as the endocytic receptor responsible for clearing hemopexin–heme complexes from circulation (pubmed.ncbi.nlm.nih.gov). This receptor is abundantly expressed on hepatocytes (liver parenchymal cells) and macrophages in the spleen, liver, and bone marrow – the key cell types that process heme and recycle its iron (en.wikipedia.org). Through CD91/LRP1-mediated endocytosis, the hemopexin–heme complex is internalized into these cells (www.frontiersin.org). The hemopexin protein itself may be degraded in lysosomes, but interestingly a portion can be recycled and returned to the plasma to bind more heme (www.frontiersin.org). Inside the cell, the heme cargo is handed off to the catabolic enzyme heme oxygenase-1 (HO-1), which breaks down heme into three products: biliverdin (rapidly converted to bilirubin), carbon monoxide (CO), and free iron (www.frontiersin.org). This reaction not only detoxifies heme but also recovers iron – the released iron is sequestered by ferritin for storage or exported via the ferroportin transporter to be reused in new red blood cell synthesis (www.frontiersin.org). The coordinated action of hemopexin and HO-1 thus constitutes a crucial heme clearance pathway, conserving iron while shielding the body from heme-induced oxidative stress.

Importantly, hemopexin functions in tandem with haptoglobin, another plasma protein that scavenges free hemoglobin. Haptoglobin binds cell-free hemoglobin dimers and facilitates their uptake by macrophages (via CD163 receptor), whereas hemopexin targets the free heme that is released from hemoglobin’s breakdown (www.frontiersin.org) (en.wikipedia.org). In acute hemolysis, haptoglobin is typically consumed first; once haptoglobin is depleted, free hemoglobin dissociates and releases heme, which is then intercepted by hemopexin (www.frontiersin.org). Hemopexin is therefore described as a second-line defense against the toxic effects of hemolysis (www.frontiersin.org). This two-tier scavenging system (Hb–haptoglobin and heme–hemopexin) is a vital part of the body’s innate response to hemolytic events or hemorrhage, preventing hemoglobin/heme-mediated oxidation of lipids and proteins in the plasma and vasculature (www.frontiersin.org).

Biological Processes and Pathways Involving Hemopexin

Through its heme-scavenging activity, hemopexin is a central player in several biological processes:

• Iron Homeostasis: By capturing free heme and delivering it to the liver and spleen for breakdown, hemopexin facilitates iron recycling (www.frontiersin.org). The iron liberated by HO-1 from hemopexin-bound heme is returned to the bone marrow (via macrophage ferroportin) to support new erythropoiesis (www.frontiersin.org). This recycling is critical because it allows reutilization of iron from senescent or damaged red cells, minimizing iron loss. In line with this role, mice lacking hemopexin show alterations in iron metabolism – for example, hemopexin knockout mice exhibit increased dietary iron absorption, presumably as a compensatory response to perceived iron insufficiency when heme iron recycling is impaired (journals.plos.org). Thus, HPX is intimately involved in systemic iron regulation, working alongside proteins like transferrin and ferritin to balance iron levels.

• Heme Metabolism and Detoxification: Hemopexin is a key component of the heme degradation pathway, partnering with HO-1. It ensures that heme is delivered to cells that express high levels of HO-1 (such as hepatocytes and splenic macrophages) for safe catabolism (www.frontiersin.org). The heme oxygenase reaction generates biliverdin and bilirubin, which are potent antioxidants, as well as CO, which has signaling functions – thereby converting a pro-oxidant heme into beneficial molecules. By triggering HO-1 activity, the hemopexin–heme uptake pathway also induces a cytoprotective gene expression program. Classic studies showed that heme taken up via hemopexin can induce HO-1 expression itself in cultured cells (pmc.ncbi.nlm.nih.gov), creating a positive feedback loop that enhances the cell’s ability to handle oxidative stress. Additionally, hemopexin-mediated heme uptake has been reported to upregulate other protective genes such as metallothionein, which binds free metals and helps neutralize oxidative damage (www.frontiersin.org). Through these mechanisms, hemopexin not only removes heme but actively initiates cellular stress responses that fortify tissues against further injury (www.frontiersin.org).

• Protection Against Oxidative Stress and Inflammation: Free heme is recognized as a pro-inflammatory danger signal (a DAMP – damage-associated molecular pattern). It can activate inflammatory pathways, for instance by triggering the alternative pathway of the complement system and by stimulating immune cells through Toll-like receptor 4, leading to release of cytokines (www.frontiersin.org). Hemopexin counters these effects by neutralizing free heme before it can engage such pathways (www.frontiersin.org). There is evidence that hemopexin has direct immunomodulatory effects: for example, one study found that adding hemopexin to macrophages suppressed LPS-induced pro-inflammatory cytokine production, suggesting hemopexin can down-regulate inflammatory signaling in a heme-dependent manner (pmc.ncbi.nlm.nih.gov). In mouse models of inflammation, hemopexin-deficient mice show exaggerated inflammatory responses. Notably, hemopexin knockout mice develop more severe experimental autoimmune encephalomyelitis (a model of multiple sclerosis) with increased Th17-cell inflammation, whereas administering exogenous hemopexin reduces disease severity (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). These findings indicate that beyond sequestering heme, hemopexin can function as an acute-phase anti-inflammatory agent, tempering immune activation during tissue injury. The anti-inflammatory effects are thought to stem largely from preventing heme-driven immune cell activation and oxidative damage, although hemopexin might also have some heme-independent modulatory roles on immune cells (pubmed.ncbi.nlm.nih.gov).

• Nutritional Immunity (Host Defense Against Pathogens): Iron is an essential nutrient for many pathogens, and free heme can be a rich iron source for invading microbes. The host’s strategy of locking up heme with hemopexin therefore also serves to withhold iron from pathogens, a facet of the immune system known as nutritional immunity. Some bacteria have evolved counter-mechanisms – for instance, Haemophilus influenzae produces a specific binding protein (HxuA) that can snatch heme from the hemopexin–heme complex (www.frontiersin.org). This tug-of-war illustrates hemopexin’s role in infection biology: under normal circumstances, hemopexin helps curb microbial growth by depriving microbes of heme, but certain pathogens can directly exploit hemopexin-bound heme. In general, however, hemopexin is considered part of the host’s defense arsenal, working to keep free heme (and iron) away from both host tissues (to prevent damage) and invading organisms (www.frontiersin.org).

Expression and Localization

Hemopexin is a secreted protein that operates mainly in the extracellular space (blood plasma and interstitial fluids). The HPX gene is highly expressed in the liver, consistent with the liver’s role as the source of most plasma proteins (www.frontiersin.org). Hepatocytes synthesize hemopexin and release it into circulation, where normal plasma concentrations range approximately from 0.5 to 1.5 mg/mL (www.frontiersin.org). Hemopexin is also detectable (at lower levels) in certain other tissues – for example, expression has been observed in the nervous system, skeletal muscle, kidneys, and retina (www.frontiersin.org). Local production in these tissues might serve to handle heme in specific microenvironments (e.g. the retina, which is highly vascular and metabolically active, or the brain where hemopexin in cerebrospinal fluid can help clear hemorrhagic heme) (pubmed.ncbi.nlm.nih.gov) (www.frontiersin.org). Nonetheless, the bulk of hemopexin’s function occurs in the circulation, binding heme in the bloodstream and then interacting with cell-surface receptors on hepatocytes and macrophages.

Within the cell, hemopexin’s life cycle is transient: after receptor-mediated endocytosis, the heme is offloaded internally and hemopexin may be degraded. However, studies suggest that hemopexin is not always irreversibly consumed – a fraction of the internalized protein can dissociate from its receptor and be secreted back into the blood for reuse (www.frontiersin.org). This recycling mechanism implies that under normal physiological conditions, hemopexin molecules shuttle between the circulation and the liver/spleen macrophages, continuously ferrying heme to safe storage or breakdown. Hemopexin is glycosylated (bearing N-linked and O-linked sugars) which increases its stability in the blood and protects it from rapid clearance (en.wikipedia.org). The stability is important because during chronic hemolysis, hemopexin needs to remain available in plasma over extended periods. In conditions of extreme heme load, hemopexin can become saturated and depleted from plasma – in such cases, excess free heme may appear in circulation once the binding capacity of hemopexin is exhausted (www.frontiersin.org). This situation underscores why hemopexin is usually present in excess under healthy conditions (high baseline levels) and why the body can upregulate HPX expression during stress.

Hemopexin is often classified as an acute-phase protein. In response to inflammatory signals (like the cytokines IL-6, IL-1β, and TNF-α), liver cells increase the production of acute-phase proteins, including those involved in iron metabolism (pubmed.ncbi.nlm.nih.gov). Indeed, IL-6 strongly induces HPX gene expression in hepatocytes, leading to elevated plasma hemopexin levels in inflammation (pubmed.ncbi.nlm.nih.gov). This makes sense biologically: during infection or tissue injury, hemolysis and cell damage are common, so boosting hemopexin provides additional capacity to sequester any heme that is released. In mice and other model organisms, hemopexin behaves as a classic acute-phase reactant – its serum levels rise significantly during inflammatory conditions (pubmed.ncbi.nlm.nih.gov). In humans, the acute-phase behavior of hemopexin is observed in certain situations, but it has been somewhat variable. Some clinical studies report increased hemopexin levels in inflammatory diseases or sepsis, whereas others find that levels drop during severe hemolysis (likely due to protein consumption) (www.frontiersin.org). There is ongoing debate about the extent to which human hemopexin should be considered an acute-phase reactant (www.frontiersin.org). Nevertheless, the current understanding is that HPX is under cytokine regulation and can be upregulated as part of the body’s concerted response to inflammation and iron imbalance, even if the magnitude of this increase in humans is modest compared to classical acute-phase proteins like C-reactive protein.

Clinical Significance and Pathophysiology

Given its role in detoxifying heme, hemopexin is pivotal in conditions involving hemolysis or hemorrhage. Genetic ablation or deficiency of hemopexin leads to heightened susceptibility to heme toxicity. Hemopexin-knockout mice, for instance, exhibit severe injuries when challenged with hemolytic stress: they suffer acute oxidative damage to the liver and kidneys and fail to adequately clear heme, confirming that hemopexin is essential for preventing heme-mediated tissue damage (pubmed.ncbi.nlm.nih.gov). In models of intracerebral hemorrhage (bleeding in the brain), mice lacking hemopexin or its partner enzyme HO-2 show exacerbated brain injury, due to the unchecked neurotoxic effects of hemoglobin breakdown products (pubmed.ncbi.nlm.nih.gov) (jneuroinflammation.biomedcentral.com). These experimental findings align with clinical observations that low hemopexin levels correlate with worse outcomes in hemolytic conditions. For example, in sickle cell disease (SCD) – a genetic disorder marked by chronic hemolysis – plasma hemopexin is often significantly depleted during vaso-occlusive crises as it is consumed binding the large amounts of free heme (pmc.ncbi.nlm.nih.gov). Patients with SCD tend to have chronically low haptoglobin and hemopexin, and this deficiency in heme scavengers is associated with increased oxidative endothelial damage and inflammation in the vasculature (www.frontiersin.org) (www.frontiersin.org). Restoring hemopexin in such contexts has shown promise: Vinchi et al. (2013) demonstrated that administering exogenous hemopexin to hemolytic mice prevented heme-induced vascular dysfunction, improving cardiovascular health in the model (www.frontiersin.org). Similarly, a 2016 study in a SCD mouse model found that hemopexin therapy mitigated inflammatory macrophage activation triggered by free heme, effectively “reverting” macrophages from a pro-inflammatory state (ashpublications.org) (pmc.ncbi.nlm.nih.gov). These results highlight hemopexin’s protective action in vivo and suggest that hemopexin depletion is a major factor in the pathology of hemolytic disorders.

Beyond hemolytic anemias, hemopexin has relevance in other clinical scenarios. In severe sepsis and infection, free heme released from damaged tissues can drive pathological inflammation and organ failure (www.frontiersin.org). A landmark study in septic mice showed that adding hemopexin improved survival by neutralizing circulating heme, pinpointing free heme as a “central mediator” of sepsis lethality (www.frontiersin.org). Hemopexin may also play a role in preeclampsia, a pregnancy complication involving hemolysis and oxidative stress: recent data indicate that decreased placental hemopexin and a related heme scavenger (α₁-microglobulin) are linked to the severity of preeclampsia, implying inadequate heme clearance contributes to the syndrome (pubmed.ncbi.nlm.nih.gov). In the central nervous system, intracranial hemorrhages (such as subarachnoid hemorrhage and intracerebral hemorrhage) unleash hemoglobin and heme into the brain tissue; here, hemopexin (produced locally by brain cells or entering via blood-brain barrier disruption) serves to bind heme and protect neurons from iron-mediated toxicity (pubmed.ncbi.nlm.nih.gov). There is interest in whether augmenting hemopexin levels in the cerebrospinal fluid after a hemorrhagic stroke could reduce secondary brain injury (since low haptoglobin and hemopexin are thought to permit more oxidative brain damage) (www.frontiersin.org). Additionally, changes in serum hemopexin levels have been studied as a biomarker for various diseases. For instance, falling hemopexin levels can signify ongoing hemolysis (as seen in autoimmune hemolytic anemia or transfusion reactions) (pubmed.ncbi.nlm.nih.gov), while unusually high levels might indicate an acute-phase response or liver upregulation. However, hemopexin is not yet a routine clinical test; haptoglobin is more commonly measured in hemolysis workups, although some experts suggest that concurrent monitoring of hemopexin could provide a more complete picture of hemolytic burden and help predict impending complications when haptoglobin is fully depleted (pmc.ncbi.nlm.nih.gov).

Therapeutic Developments and Expert Perspectives (2023–2024)

Recent research (2023–2024) has reinforced the importance of hemopexin in hemolytic and inflammatory conditions, while also exploring its potential as a therapeutic agent. A comprehensive 2023 review by Li et al. notes that hemopexin serves as an “effective antagonist” against heme toxicity in both acute and chronic hemolysis, and that fluctuations in HPX levels could act as a biomarker of disease progression in hemolytic disorders (www.frontiersin.org). The same review highlights that supplementing hemopexin is broadly beneficial in models of sickle cell disease, sepsis, atherosclerosis, and thrombosis – attenuating tissue damage and inflammation in these settings (www.frontiersin.org). These findings have spurred efforts to translate hemopexin therapy to the clinic. Notably, as of 2023 a Phase 1 clinical trial is underway testing plasma-derived hemopexin infusions in patients with sickle cell anemia, evaluating the safety and tolerability of repleting hemopexin during vaso-occlusive crises (www.frontiersin.org). The rationale is that providing exogenous hemopexin will bind the excess free heme in circulation during a sickle crisis, thereby preventing endothelial injury, pain, and organ damage. Early preclinical studies support this approach: for example, Gentinetta et al. (2021) showed in a mouse model of sickle cell vaso-occlusion that hemopexin infusion reduced vascular stasis and inflammation (pmc.ncbi.nlm.nih.gov) (www.mdpi.com). If such therapy proves effective, it could join haptoglobin and other extracellular scavengers as a novel treatment to manage hemolysis-driven complications.

Experts do caution, however, that hemopexin’s role can be context-dependent. In certain scenarios, hemopexin may have a “double-edged” effect (www.frontiersin.org). For instance, in infections caused by heme-scavenging bacteria (like H. influenzae or some fungi), raising hemopexin levels might inadvertently supply more heme to the pathogen, potentially worsening the infection (www.frontiersin.org) (www.frontiersin.org). Moreover, in the absence of haptoglobin, hemopexin alone cannot neutralize the toxicity of free hemoglobin’s globin components. A recent analysis of intracerebral hemorrhage models suggests that if haptoglobin is lacking, giving hemopexin by itself may not fully prevent brain injury – the heme will be cleared but the remaining free globin chains can still cause neurotoxicity (www.frontiersin.org). In such cases, a combination therapy (supplying both haptoglobin and hemopexin) might be necessary to comprehensively counteract all harmful by-products of hemolysis (www.frontiersin.org). These insights from 2023 underscore that while enhancing hemopexin is broadly protective, the full clinical strategy might need to account for other factors (like co-administering haptoglobin or addressing specific pathogens).

Overall, authoritative reviews and recent studies converge on the view that hemopexin is a critical protective factor in the face of hemolytic stress (www.frontiersin.org). Its capacity to safely chaperone heme not only prevents immediate oxidative damage but also influences signaling pathways (such as HO-1 induction and cytokine modulation) that have far-reaching effects on immunity and metabolism. As research from 2023–2024 indicates, augmenting the hemopexin pathway holds therapeutic promise for diseases ranging from sickle cell anemia to sepsis. At the same time, ongoing investigations are refining our understanding – for example, clarifying hemopexin’s behavior as an acute-phase reactant in humans, and delineating situations where hemopexin might need support from other interventions. The consensus, however, remains that HPX is indispensable for heme detoxification and iron reutilization, anchoring a conservation system that is vital for maintaining cellular health in the face of blood cell destruction (www.frontiersin.org) (www.frontiersin.org).

Conclusion: Hemopexin is a paradigmatic example of a protective plasma glycoprotein with a specialized role – it binds and transports free heme, thereby safeguarding the body from heme’s toxic effects and recycling its iron. It operates primarily in the bloodstream and endocytic compartments of the liver and spleen, connecting the events of hemoglobin breakdown to downstream metabolic pathways like bilirubin production and iron recovery. By integrating with inflammatory and oxidative stress responses, hemopexin also modulates biological pathways beyond mere heme transport, contributing to immunological homeostasis. Decades of biochemical and genetic studies have established the core functions of hemopexin, and recent research (including studies from 2023–2024) continues to expand this knowledge, revealing new therapeutic angles and nuanced roles in disease. In summary, the human HPX gene product is a key defender against heme toxicity and a facilitator of iron metabolism, with its importance manifest in both everyday physiology (scavenging heme from normal red cell turnover) and in extreme pathological conditions (where its absence or depletion leads to tissue damage). Ongoing clinical investigations aim to harness hemopexin’s heme-binding power to treat hemolytic diseases, exemplifying how understanding a gene’s fundamental function can inform real-world medical applications (www.frontiersin.org) (www.frontiersin.org).

References:

1. Bakker, W.W., et al. (2003). Kidney International – Production of hemopexin by TNF-α stimulated human mesangial cells (bmcneurosci.biomedcentral.com).

2. Tolosano, E., et al. (2010). Antioxidants & Redox Signaling – Defective recovery and severe renal damage after acute hemolysis in hemopexin-knockout mice (pmc.ncbi.nlm.nih.gov).

3. Hvidberg, V., et al. (2005). Blood, 106(7): 2572–2579 – Identification of the receptor scavenging hemopexin–heme complexes (LRP/CD91) (pubmed.ncbi.nlm.nih.gov).

4. Miller, Y.I., & Shaklai, N. (1999). Biochim. Biophys. Acta, 1454: 153–164 – Kinetics of hemin distribution in plasma and heme’s transfer to hemopexin (www.frontiersin.org).

5. Larsen, R., et al. (2010). Sci. Transl. Med., 2(51): 51ra71 – A central role for free heme in the pathogenesis of severe sepsis (www.frontiersin.org).

6. Li, Y., et al. (2023). Front. Immunol., 14: 1274333 – Double-edged functions of hemopexin in hematological diseases: basic mechanisms to clinical application (www.frontiersin.org) (www.frontiersin.org).

7. Zhang, X., et al. (2014). J. Immunology, 193(1): 302–311 – Acute-phase protein hemopexin is a negative regulator of Th17 responses (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov).

8. Vinchi, F., et al. (2013). Circulation, 127(12): 1317–1329 – Hemopexin therapy improves cardiovascular function by preventing heme-induced toxicity in hemolytic models (www.frontiersin.org).

9. Frontiers in Immunology (2023) – Figure 1 illustration of hemoglobin/heme scavenging pathways (HPX–heme via CD91, Hp–Hb via CD163) (www.frontiersin.org) (www.frontiersin.org).

10. Gentinetta, T., et al. (2021). Int. J. Mol. Sci. 22(12): 6408 – Plasma-derived hemopexin as a therapeutic in sickle cell vaso-occlusion (preclinical evidence) (pmc.ncbi.nlm.nih.gov) (www.mdpi.com).

Citations

1. AnnotationURLCitation(end_index=397, start_index=233, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti')
2. AnnotationURLCitation(end_index=749, start_index=552, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=a%20plasma%20glycoprotein%20composed%20of,heme%20transport%2C%20and%20preventing%20peroxidation')
3. AnnotationURLCitation(end_index=915, start_index=750, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=concentrations,activity%20affects%20skeletal%20muscle%20aerobic')
4. AnnotationURLCitation(end_index=1237, start_index=1087, title='Hemopexin', type='url_citation', url='https://en.wikipedia.org/wiki/Hemopexin#:~:text=single%20polypeptide%20chain%20of%20439,in%20amino%20acid%20sequence%20suggested')
5. AnnotationURLCitation(end_index=1515, start_index=1377, title='Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17185359/#:~:text=The%20heme,dimerization%2C%20binding%20of%20substrates%20or')
6. AnnotationURLCitation(end_index=1854, start_index=1716, title='Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17185359/#:~:text=The%20heme,dimerization%2C%20binding%20of%20substrates%20or')
7. AnnotationURLCitation(end_index=2019, start_index=1855, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti')
8. AnnotationURLCitation(end_index=2764, start_index=2601, title='Identification of the receptor scavenging hemopexin-heme complexes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/15947085/#:~:text=Heme%20released%20from%20heme,related%20protein%20%28LRP%29%2FCD91%2C%20a%20receptor')
9. AnnotationURLCitation(end_index=3114, start_index=2939, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015')
10. AnnotationURLCitation(end_index=3535, start_index=3338, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=a%20plasma%20glycoprotein%20composed%20of,heme%20transport%2C%20and%20preventing%20peroxidation')
11. AnnotationURLCitation(end_index=3827, start_index=3663, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti')
12. AnnotationURLCitation(end_index=4177, start_index=4002, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Initially%2C%20heme%20binds%20to%20lipoproteins,transporter%20ferroportin')
13. AnnotationURLCitation(end_index=4545, start_index=4370, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015')
14. AnnotationURLCitation(end_index=5020, start_index=4857, title='Identification of the receptor scavenging hemopexin-heme complexes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/15947085/#:~:text=Heme%20released%20from%20heme,related%20protein%20%28LRP%29%2FCD91%2C%20a%20receptor')
15. AnnotationURLCitation(end_index=5324, start_index=5161, title='Identification of the receptor scavenging hemopexin-heme complexes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/15947085/#:~:text=Heme%20released%20from%20heme,related%20protein%20%28LRP%29%2FCD91%2C%20a%20receptor')
16. AnnotationURLCitation(end_index=5663, start_index=5519, title='Hemopexin', type='url_citation', url='https://en.wikipedia.org/wiki/Hemopexin#:~:text=then%20be%20oxidized%20into%20free,spleen%2C%20liver%20and%20bone%20marrow')
17. AnnotationURLCitation(end_index=5950, start_index=5769, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=The%20heme%20detoxification%20process%20is,organ%20tissues%2C%20including%20the')
18. AnnotationURLCitation(end_index=6281, start_index=6100, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=The%20heme%20detoxification%20process%20is,organ%20tissues%2C%20including%20the')
19. AnnotationURLCitation(end_index=6672, start_index=6511, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=heme%20is%20a%20crucial%20step,Free%20heme%20can%20activate')
20. AnnotationURLCitation(end_index=7053, start_index=6892, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=heme%20is%20a%20crucial%20step,Free%20heme%20can%20activate')
21. AnnotationURLCitation(end_index=7725, start_index=7550, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015')
22. AnnotationURLCitation(end_index=7901, start_index=7726, title='Hemopexin', type='url_citation', url='https://en.wikipedia.org/wiki/Hemopexin#:~:text=Hemopexin%20is%20different%20from%20haptoglobin,Haptoglobin%20%C2%A7%20Differentiation%20with%20hemopexin')
23. AnnotationURLCitation(end_index=8235, start_index=8080, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=where%20it%20is%20reused%20to,2%20%2C%20%2025%2C%2015')
24. AnnotationURLCitation(end_index=8513, start_index=8338, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015')
25. AnnotationURLCitation(end_index=8938, start_index=8763, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015')
26. AnnotationURLCitation(end_index=9407, start_index=9246, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=heme%20is%20a%20crucial%20step,Free%20heme%20can%20activate')
27. AnnotationURLCitation(end_index=9713, start_index=9552, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=heme%20is%20a%20crucial%20step,Free%20heme%20can%20activate')
28. AnnotationURLCitation(end_index=10290, start_index=10113, title='Lack of Plasma Protein Hemopexin Results in Increased Duodenal Iron Uptake | PLOS One', type='url_citation', url='https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0068146#:~:text=Lack%20of%20Plasma%20Protein%20Hemopexin,288.%2014.%2014.%20Vinchi%20F')
29. AnnotationURLCitation(end_index=10894, start_index=10712, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=heme%20is%20a%20crucial%20step,complement%20system%20through%20the%20alternative')
30. AnnotationURLCitation(end_index=11492, start_index=11329, title='Critical Role of Hemopexin Mediated Cytoprotection in the Pathophysiology of Sickle Cell Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8232622/#:~:text=Critical%20Role%20of%20Hemopexin%20Mediated,of%20Sickle%20Cell%20Disease%20Rani')
31. AnnotationURLCitation(end_index=11924, start_index=11776, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=typically%20circulates%20in%20human%20plasma,3')
32. AnnotationURLCitation(end_index=12229, start_index=12081, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=typically%20circulates%20in%20human%20plasma,3')
33. AnnotationURLCitation(end_index=12786, start_index=12611, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015')
34. AnnotationURLCitation(end_index=13057, start_index=12882, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015')
35. AnnotationURLCitation(end_index=13451, start_index=13349, title='Hemopexin down-regulates LPS-induced proinflammatory cytokines from macrophages - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2726768/#:~:text=Hemopexin%20down,2')
36. AnnotationURLCitation(end_index=13955, start_index=13791, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti')
37. AnnotationURLCitation(end_index=14123, start_index=13956, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=higher%20production%20of%20Th17%20differentiating,has%20a%20negative%20regulatory%20role')
38. AnnotationURLCitation(end_index=14685, start_index=14521, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti')
39. AnnotationURLCitation(end_index=15408, start_index=15220, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Figure%C2%A02%20Mechanisms%20to%20acquire%20heme,and%20mediates%20heme%20release%20for')
40. AnnotationURLCitation(end_index=16016, start_index=15828, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Figure%C2%A02%20Mechanisms%20to%20acquire%20heme,and%20mediates%20heme%20release%20for')
41. AnnotationURLCitation(end_index=16458, start_index=16293, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=concentrations,activity%20affects%20skeletal%20muscle%20aerobic')
42. AnnotationURLCitation(end_index=16768, start_index=16603, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=concentrations,activity%20affects%20skeletal%20muscle%20aerobic')
43. AnnotationURLCitation(end_index=17111, start_index=16946, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=concentrations,activity%20affects%20skeletal%20muscle%20aerobic')
44. AnnotationURLCitation(end_index=17521, start_index=17358, title='Identification of the receptor scavenging hemopexin-heme complexes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/15947085/#:~:text=Heme%20released%20from%20heme,related%20protein%20%28LRP%29%2FCD91%2C%20a%20receptor')
45. AnnotationURLCitation(end_index=17687, start_index=17522, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=concentrations,activity%20affects%20skeletal%20muscle%20aerobic')
46. AnnotationURLCitation(end_index=18413, start_index=18232, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=The%20heme%20detoxification%20process%20is,organ%20tissues%2C%20including%20the')
47. AnnotationURLCitation(end_index=18934, start_index=18784, title='Hemopexin', type='url_citation', url='https://en.wikipedia.org/wiki/Hemopexin#:~:text=single%20polypeptide%20chain%20of%20439,in%20amino%20acid%20sequence%20suggested')
48. AnnotationURLCitation(end_index=19451, start_index=19270, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=The%20heme%20detoxification%20process%20is,organ%20tissues%2C%20including%20the')
49. AnnotationURLCitation(end_index=20045, start_index=19881, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti')
50. AnnotationURLCitation(end_index=20341, start_index=20177, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti')
51. AnnotationURLCitation(end_index=20858, start_index=20694, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti')
52. AnnotationURLCitation(end_index=21289, start_index=21168, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=agent%20in%20heme,8')
53. AnnotationURLCitation(end_index=21527, start_index=21406, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=agent%20in%20heme,8')
54. AnnotationURLCitation(end_index=22545, start_index=22374, title='Hemopexin prevents endothelial damage and liver congestion in a mouse model of heme overload - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18556779/#:~:text=Hemopexin%20prevents%20endothelial%20damage%20and,proteins%20protect%20from%20renal%20damage')
55. AnnotationURLCitation(end_index=22914, start_index=22764, title='Deletion of the hemopexin or heme oxygenase-2 gene aggravates brain injury following stroma-free hemoglobin-induced intracerebral hemorrhage - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26831741/#:~:text=Deletion%20of%20the%20hemopexin%20or,not%20just%20blue%3A%20a%20concise')
56. AnnotationURLCitation(end_index=23096, start_index=22915, title='Deletion of the hemopexin or heme oxygenase-2 gene aggravates brain injury following stroma-free hemoglobin-induced intracerebral hemorrhage | Journal of Neuroinflammation | Full Text', type='url_citation', url='https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-016-0490-1#:~:text=Deletion%20of%20the%20hemopexin%20or,44%5D%2C%20and')
57. AnnotationURLCitation(end_index=23619, start_index=23472, title='Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10653390/#:~:text=basic%20mechanisms%20to%20clinical%20application,Ann%20Hematol')
58. AnnotationURLCitation(end_index=24002, start_index=23828, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=lipoproteins%20%28LDL%29%20%285%20%29,as%20an%20acute%20phase%20reactant')
59. AnnotationURLCitation(end_index=24114, start_index=24003, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=22,130179')
60. AnnotationURLCitation(end_index=24470, start_index=24359, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=22,130179')
61. AnnotationURLCitation(end_index=24857, start_index=24681, title='Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease | Blood | American Society of Hematology', type='url_citation', url='https://ashpublications.org/blood/article/127/4/473/35037/Hemopexin-therapy-reverts-heme-induced#:~:text=Hemopexin%20therapy%20reverts%20heme,for%20HbA')
62. AnnotationURLCitation(end_index=24982, start_index=24858, title='Increased Striatal Injury and Behavioral Deficits after Intracerebral Hemorrhage in Hemopexin Knockout Mice - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3061252/#:~:text=,severe%20renal%20damage%20after%20acute')
63. AnnotationURLCitation(end_index=25468, start_index=25356, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=62,3001118')
64. AnnotationURLCitation(end_index=25782, start_index=25649, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=match%20at%20L1182%2062,3001118')
65. AnnotationURLCitation(end_index=26238, start_index=26125, title='Hemopexin and α1-microglobulin heme scavengers with differential involvement in preeclampsia and fetal growth restriction - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/32915914/#:~:text=Hemopexin%20and%20%CE%B11,articles')
66. AnnotationURLCitation(end_index=26729, start_index=26579, title='Deletion of the hemopexin or heme oxygenase-2 gene aggravates brain injury following stroma-free hemoglobin-induced intracerebral hemorrhage - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26831741/#:~:text=Deletion%20of%20the%20hemopexin%20or,not%20just%20blue%3A%20a%20concise')
67. AnnotationURLCitation(end_index=27072, start_index=26966, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=82,2')
68. AnnotationURLCitation(end_index=27417, start_index=27316, title='Human Plasma and Recombinant Hemopexins: Heme Binding Revisited - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/33530421/#:~:text=PubMed%20pubmed,Vinchi')
69. AnnotationURLCitation(end_index=27979, start_index=27832, title='Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10653390/#:~:text=basic%20mechanisms%20to%20clinical%20application,Ann%20Hematol')
70. AnnotationURLCitation(end_index=28660, start_index=28489, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=It%20is%20now%20understood%20that,such%20as%20sickle%20cell%20disease')
71. AnnotationURLCitation(end_index=29075, start_index=28877, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Consistent%20with%20the%20findings%20of,by%20certain%20pathogens%2C%20intracerebral%20hemorrhage')
72. AnnotationURLCitation(end_index=29591, start_index=29395, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=therapy%20for%20hemolytic%20disorders%20with,focusing%20on%20safety%2C%20tolerability%2C%20and')
73. AnnotationURLCitation(end_index=30124, start_index=29986, title='Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8836474/#:~:text=Plasma,are%20precipitated%20using%20ammonium%20sulfate')
74. AnnotationURLCitation(end_index=30207, start_index=30125, title='Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence', type='url_citation', url='https://www.mdpi.com/2077-0383/11/3/630#:~:text=Plasma,Occlusion')
75. AnnotationURLCitation(end_index=30687, start_index=30516, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=It%20is%20now%20understood%20that,such%20as%20sickle%20cell%20disease')
76. AnnotationURLCitation(end_index=31095, start_index=30907, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Figure%C2%A02%20Mechanisms%20to%20acquire%20heme,and%20mediates%20heme%20release%20for')
77. AnnotationURLCitation(end_index=31294, start_index=31096, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Consistent%20with%20the%20findings%20of,by%20certain%20pathogens%2C%20intracerebral%20hemorrhage')
78. AnnotationURLCitation(end_index=31852, start_index=31674, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=ultimately%20exacerbating%20iron,77%5D.%20When%20administered%20systemically')
79. AnnotationURLCitation(end_index=32198, start_index=32020, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=ultimately%20exacerbating%20iron,77%5D.%20When%20administered%20systemically')
80. AnnotationURLCitation(end_index=32785, start_index=32587, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Consistent%20with%20the%20findings%20of,by%20certain%20pathogens%2C%20intracerebral%20hemorrhage')
81. AnnotationURLCitation(end_index=33820, start_index=33645, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015')
82. AnnotationURLCitation(end_index=33995, start_index=33821, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=lipoproteins%20%28LDL%29%20%285%20%29,as%20an%20acute%20phase%20reactant')
83. AnnotationURLCitation(end_index=35581, start_index=35407, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=lipoproteins%20%28LDL%29%20%285%20%29,as%20an%20acute%20phase%20reactant')
84. AnnotationURLCitation(end_index=35778, start_index=35582, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=therapy%20for%20hemolytic%20disorders%20with,focusing%20on%20safety%2C%20tolerability%2C%20and')
85. AnnotationURLCitation(end_index=36129, start_index=35923, title='Hemopexin induces neuroprotection in the rat subjected to focal cerebral ischemia | BMC Neuroscience | Full Text', type='url_citation', url='https://bmcneurosci.biomedcentral.com/articles/10.1186/1471-2202-14-58#:~:text=Hemopexin%20induces%20neuroprotection%20in%20the,Tolosano%20E%2C%20Fagoonee%20S%2C%20Morello')
86. AnnotationURLCitation(end_index=36417, start_index=36293, title='Increased Striatal Injury and Behavioral Deficits after Intracerebral Hemorrhage in Hemopexin Knockout Mice - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3061252/#:~:text=,severe%20renal%20damage%20after%20acute')
87. AnnotationURLCitation(end_index=36728, start_index=36565, title='Identification of the receptor scavenging hemopexin-heme complexes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/15947085/#:~:text=Heme%20released%20from%20heme,related%20protein%20%28LRP%29%2FCD91%2C%20a%20receptor')
88. AnnotationURLCitation(end_index=37067, start_index=36892, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Initially%2C%20heme%20binds%20to%20lipoproteins,transporter%20ferroportin')
89. AnnotationURLCitation(end_index=37342, start_index=37209, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=match%20at%20L1182%2062,3001118')
90. AnnotationURLCitation(end_index=37695, start_index=37514, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=The%20heme%20detoxification%20process%20is,organ%20tissues%2C%20including%20the')
91. AnnotationURLCitation(end_index=37817, start_index=37696, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=agent%20in%20heme,8')
92. AnnotationURLCitation(end_index=38126, start_index=37962, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti')
93. AnnotationURLCitation(end_index=38294, start_index=38127, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=higher%20production%20of%20Th17%20differentiating,has%20a%20negative%20regulatory%20role')
94. AnnotationURLCitation(end_index=38587, start_index=38476, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=22,130179')
95. AnnotationURLCitation(end_index=38899, start_index=38724, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015')
96. AnnotationURLCitation(end_index=39015, start_index=38900, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=FIGURE%C2%A01')
97. AnnotationURLCitation(end_index=39327, start_index=39189, title='Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8836474/#:~:text=Plasma,are%20precipitated%20using%20ammonium%20sulfate')
98. AnnotationURLCitation(end_index=39410, start_index=39328, title='Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence', type='url_citation', url='https://www.mdpi.com/2077-0383/11/3/630#:~:text=Plasma,Occlusion')

Hemopexin (HPX): A Comprehensive Analysis of Gene Function, Molecular Mechanisms, and Biological Roles

Executive Summary

Hemopexin (HPX), encoded by the HPX gene located at chromosome 11p15.5-p15.4 in humans, is a plasma glycoprotein that serves as the highest-affinity heme-binding protein known in the human proteome, with extraordinary binding affinity for heme that exceeds all other known proteins[1][14]. This 60-kDa glycoprotein circulates in plasma at concentrations of 0.5–1.5 mg/mL and functions as a critical component of the body's defense system against heme toxicity by scavenging free heme released from hemoproteins during hemolysis, hemorrhage, and other pathological states[1][5][51]. Beyond its primary heme-scavenging role, hemopexin participates in complex receptor-mediated endocytosis, iron homeostasis, inflammatory regulation, and tissue protection across multiple organ systems including the liver, central nervous system, and immune tissues[1][7][8]. The protein undergoes receptor-specific internalization through the low-density lipoprotein receptor-related protein 1 (LRP1/CD91) and potentially through transferrin receptor-mediated pathways, leading to heme catabolism, iron recycling, and the induction of protective antioxidant responses within target cells[7][8][43]. Recent evidence has expanded understanding of hemopexin beyond classical heme detoxification, revealing its involvement in immune regulation, neurogenesis, skeletal muscle signaling, and cardiovascular homeostasis, establishing it as a multifunctional acute-phase protein with both protective and context-dependent harmful effects depending on tissue location and disease state.

Gene Structure, Organization, and Genomic Localization

The HPX gene, encoding hemopexin, exhibits a well-characterized genomic organization that reflects its evolutionary history and functional domains. The gene spans approximately 12 kilobases and is organized into 9 exons interrupted by 8 introns, with remarkable structural symmetry that suggests duplication of an ancestral gene during evolution[1]. The direct correspondence between exons and the 10 repeating units identified in the hemopexin protein sequence indicates that the gene's organization mirrors the protein's structural organization, a feature that has been conserved throughout evolutionary time[1]. The introns are not positioned randomly within the gene; rather, they fall in the center of regions of amino acid sequence homology in strikingly similar locations in six of the ten protein units and in a symmetric position in each half of the coding sequence[1]. This organizational symmetry suggests that hemopexin consists of two similar structural halves connected by a central hinge region, a feature that has profound implications for the protein's three-dimensional structure and heme-binding mechanism[1].

The HPX gene has been precisely mapped to human chromosome 11 at position 11p15.5-p15.4, the same chromosomal location as the beta-globin gene complex[1]. This chromosomal assignment was accomplished through Southern blot analysis of human/hamster hybrid cells containing different combinations of human chromosomes and confirmed through in situ hybridization studies[1]. The proximity of the HPX gene to the beta-globin locus may reflect coordinated regulation during hemolytic stress, as both gene products are involved in hemoglobin metabolism and response to hemolysis. The genomic organization and chromosomal localization of HPX have remained consistent across published studies, providing confidence in the accuracy of this genetic mapping. The primary structure of human hemopexin has been deduced through sequence analysis of peptides obtained from chemical and enzymatic digests, revealing that the protein consists of approximately 440 amino acid residues and contains about 20% carbohydrate by mass[32][35].

Notably, hemopexin contains unique glycosylation features including one galactosamine oligosaccharide linked O-glycosidically to the amino-terminal threonine residue and five glucosamine oligosaccharides attached at N-glycosylation sites following the consensus sequence Asn-X-Thr/Ser[32][35]. The galactosamine oligosaccharide at the amino terminus is unusual and had not been previously identified in hemopexin before detailed structural analysis, demonstrating the complexity of hemopexin's post-translational modifications[32][35]. These glycosylation sites are distributed throughout the protein: the galactosamine and one glucosamine are located in the amino-terminal region, three glucosamine oligosaccharides are in the middle region, and one glucosamine is in the carboxyl-terminal region[35]. The structural analysis revealed that hemopexin contains eighteen tryptophan residues arranged in four unusual clusters, with each cluster containing three to four tryptophan residues separated by zero to twelve intervening amino acids[32][35]. Twelve of the eighteen tryptophans are conserved in homologous positions, suggesting functional importance of this clustering[1]. Additionally, the histidine residues in hemopexin are clustered in a histidine-rich sequence in the middle region where histidines flank beta-turns presumably located at the protein surface[35].

Gene Expression Pattern and Regulation

The transcriptional regulation of the HPX gene exhibits tissue-specific patterns with marked preferential expression in hepatocytes, although expression occurs in other tissues under specific conditions. Early studies using specific complementary DNA probes demonstrated that the HPX gene is expressed predominantly in the liver, with expression below detection limits in most other tissues or cell lines examined[1]. Using S1 mapping analysis, the transcription initiation site in hepatic cells was located 28 base pairs upstream from the AUG initiation codon of the hemopexin gene, establishing the precise point at which transcription of the primary hepatic hemopexin message begins[1]. However, subsequent research has revealed that HPX expression extends to multiple extrahepatic tissues including the nervous system, skeletal muscle, retina, and kidney[5][51][54]. In the central nervous system specifically, hemopexin is expressed by both neurons and glial cells and can be synthesized intrathecally, contributing to cerebrospinal fluid hemopexin levels that are approximately tenfold lower than those in plasma[5][51].

The regulation of hemopexin gene expression is controlled by the acute-phase response pathway, whereby the synthesis of HPX is induced during infection and inflammatory states through signaling by pro-inflammatory cytokines. Hemopexin and haptoglobin are both classified as acute-phase proteins, the synthesis of which are induced during infection and after inflammatory states to minimize tissue injury and facilitate tissue repair[1]. The specific cytokines that induce hemopexin synthesis include interleukin-6 (IL-6), interleukin-1 beta (IL-1β), and tumor necrosis factor-alpha (TNF-α), which act on hepatocytes to increase transcription of the HPX gene[20]. A type II interleukin-6 response element has been identified within the hemopexin gene, indicating direct induction through the IL-6 signaling pathway[28]. Notably, hemopexin mRNA levels increase not only during infection and inflammation but also in response to certain forms of systemic stress; hemopexin mRNA levels were notably elevated in rodent models subjected to sham abdominal surgery or partial hepatectomy, indicating responsiveness to surgical stress and tissue injury[5][51].

The acute-phase response regulation of hemopexin contrasts with constitutive expression patterns in extrahepatic tissues. In extrahepatic sites such as nervous system, skeletal muscle, and retina, hemopexin appears to be constitutively expressed at lower levels, suggesting local production to support tissue-specific functions. This tissue-specific expression pattern indicates that hemopexin has both systemic roles (through hepatic production and plasma circulation) and local tissue roles (through local synthesis). Age-related changes in plasma hemopexin levels have been documented, with hemopexin levels increasing from an average of 60 mg/100 mL (range 40–70) in individuals aged 1–12 years to an average of 77 mg/100 mL (range 66–100) in individuals aged 20–40 years, but then declining to 50–80 mg/100 mL in individuals aged 50–70 years[55]. These age-related variations in hemopexin levels may reflect changes in hepatic synthesis capacity and altered susceptibility to hemolytic stress.

Primary Function: Heme Binding with Extraordinary Affinity

The primary and most extensively characterized function of hemopexin is the binding and scavenging of free heme with affinity exceeding all other known proteins in the human proteome. Hemopexin binds heme with the highest affinity of any known protein, with a dissociation constant (Kd) estimated at less than 10^-13 M[1][22], representing binding affinity that is extraordinary even among high-affinity protein-ligand interactions. This extraordinary binding affinity enables hemopexin to effectively remove free heme from the circulation and tissues, preventing the oxidative damage and inflammatory effects that free heme causes[1]. The main function of hemopexin is scavenging the heme released or lost by the turnover of heme proteins such as hemoglobin and thus protecting the body from the oxidative damage that free heme can cause[1]. The binding stoichiometry of hemopexin with heme exhibits concentration-dependent behavior, exhibiting a 1:1 binding ratio at low heme concentrations and at least a 2:1 ratio (heme:hemopexin) at higher heme concentrations[5][51].

The molecular basis for hemopexin's exceptional heme-binding affinity has been elucidated through crystallographic analysis of the rabbit hemopexin-heme complex, revealing structural features that provide both extraordinary binding strength and controlled heme release[14][17]. The crystal structure reveals that hemopexin has four-bladed β-propeller folding motifs that are similar in the N- and C-terminal domains, joined by a flexibly structured hinge sequence[2]. The heme binding site is formed between these two similar four-bladed β-propeller domains and is bounded by the interdomain linker region[14][17]. The ligand is bound to two histidine residues (identified as H236 and H293) in the linker region in a pocket dominated by aromatic and basic groups[14][17]. Further stabilization of the heme-hemopexin complex is achieved by the association of the two β-propeller domains, which form an extensive polar interface that includes a cushion of ordered water molecules[14][17].

Detailed molecular docking and spot-synthesis studies have identified specific amino acid residues critical for heme binding within hemopexin. Seven linear peptide sequences in hemopexin were identified to bind hemin (designated H1–H7), with histidine residues playing particularly important roles in heme coordination[2]. The amino acid composition analysis of these identified heme-binding sequences demonstrated that histidine residues are relevant for heme binding, with H105, H293, H373, H400, H429, and H462 being distributed across the H1–H7 peptide sequences[2]. H293 was present in the H3 peptide sequence with particularly high hemin binding capacity, showing a signal of approximately 50%, while H373 was present in peptides with the highest signal spots exceeding 90%[2]. Molecular dynamic simulations have revealed that tyrosine residues (Y646 and Y642) coordinate with heme iron, and during heme transfer, two serine residues (S557 and S563) capture heme[2]. These findings indicate that while histidine residues coordinate the heme iron axially, a broader network of aromatic and polar amino acids contributes to both heme binding and the subsequent release process.

The mechanism by which hemopexin maintains both high binding affinity and the ability to release heme for cellular internalization represents an elegant example of protein evolution. The dual function of heme binding and release appears to be mechanically facilitated by the two β-propeller domains whose flexibility allows conformational changes upon receptor binding. When hemopexin binds to its receptor (LRP1), conformational changes in the protein likely promote heme release, allowing the bound heme to be transferred to intracellular heme-processing machinery. This mechanism ensures that heme remains sequestered and inactive during circulation but becomes available for cellular processing upon reaching target cells.

Molecular Characterization of Heme Transfer and Oxidation States

The process of heme transfer from hemoglobin to hemopexin occurs through a multistage mechanism coordinated by oxidation states of the heme. Studies highlight that the heme moiety can be transferred from hemoglobin to hemopexin, and this transfer preferentially occurs when heme is oxidized to its ferric form[2]. The heme group transfer to hemopexin is coordinated preferentially when heme moieties are oxidized to their ferric form, and the process appears to proceed in a four-stage process in which hemopexin successively transfers all four heme groups from the hemoglobin tetramer, first binding to the hemoglobin β chains, followed by loss from the hemoglobin α chains[2]. This sequential transfer pattern reflects the structural asymmetry of the hemoglobin tetramer and the differential accessibility of heme groups within the hemoglobin quaternary structure.

Within the plasma compartment, heme exhibits complex dynamics involving multiple binding proteins. Initially, free heme binds to lipoproteins in the plasma before gradually transitioning to albumin and then to hemopexin[5][11][51][58]. This sequential binding reflects the relative concentrations of these proteins in plasma and their respective heme-binding affinities. While albumin and lipoproteins can bind heme, these complexes are relatively unstable and prone to dissociation, allowing heme to transfer to hemopexin as the high-affinity end-point receptor[2][58]. The inhibitory effect of hemopexin can be mitigated by the presence of human serum albumin, and hemin is gradually transferred to hemopexin from albumin rather than initially binding to hemopexin when released in physiologically relevant protein mixtures[11][51].

Cellular Localization and Subcellular Compartmentalization

Hemopexin circulates as a plasma protein but functions in multiple cellular and tissue compartments through both systemic delivery and local tissue production. The primary site of hemopexin synthesis is the liver, where hepatocytes represent the major source of circulating hemopexin[1][5][51][54]. While primarily expressed by the liver, hemopexin is also found in tissues such as the nervous system, skeletal muscle, retina, and kidney[5][51]. The presence of hemopexin in cerebrospinal fluid represents another site of hemopexin localization, with hemopexin being expressed by ependymal cells that line the ventricular system and by neurons and glia in the central nervous system[26][51]. However, hemopexin levels in the cerebrospinal fluid are approximately tenfold lower than those in circulation, suggesting a relatively low capacity for heme binding in the brain which can become easily overwhelmed in pathological states[5][51].

At the cellular level, hemopexin enters cells through receptor-mediated endocytosis following binding to the LRP1/CD91 receptor on the cell surface. Following ligand binding, hemopexin-heme complexes are internalized via clathrin-mediated endocytosis and are transported through the endosomal pathway. Recent studies demonstrate that heme–hemopexin, which regulates cell iron homeostasis and proliferation/cell growth, is taken up by clathrin-mediated endocytosis and delivers ferrous iron safely to the iron-responsive element/iron regulatory protein (IRE/IRP) system of translational regulation[8][43]. Once internalized, hemopexin is transported to lysosomes where the complex is dissociated by lysosomal proteases, releasing the heme for further metabolism[7][43]. Some hemopexin may be recycled intact back to the plasma, particularly in certain cell types that express alternative hemopexin receptors, while in hepatocytes and macrophages, a substantial portion undergoes lysosomal degradation[7][8][43][46].

Evidence for alternative hemopexin uptake pathways has emerged from studies in cell lines lacking LRP1 expression. Hemopexin trafficking in LRP1-deficient HL-60 cells (which lack immunologically detectable LRP1) shows co-localization with transferrin and transferrin receptor 1 (TfR1) in Rab5-positive early endosomes, supporting a clathrin-mediated endocytotic pathway used by transferrin receptors[8][43]. This observation suggests that at least one other receptor system for heme–hemopexin uptake and apo-hemopexin recycling exists beyond the well-characterized LRP1 pathway[8][43]. In LRP1-expressing HepG2 hepatoma cells, hemopexin co-localizes with both TfR1 and transferrin receptor 2 (TfR2), implicating these receptors in hepatic hemopexin uptake[8][43]. These findings indicate that hemopexin endocytosis is not limited to a single receptor pathway but rather employs multiple receptor systems depending on tissue type and cell-specific receptor expression patterns.

Receptor-Mediated Endocytosis: The LRP1/CD91 Pathway

The identification and characterization of the hemopexin-heme receptor represents a major advance in understanding hemopexin's cellular functions. Using a ligand-affinity approach, the human hemopexin-heme receptor was purified and identified as the low-density lipoprotein receptor-related protein (LRP)/CD91, a multifunctional scavenger receptor expressed in several cell types including macrophages, hepatocytes, neurons, and syncytiotrophoblasts[7][50]. Binding experiments, including surface plasmon resonance (Biacore) analysis, showed that hemopexin-heme complex formation elicits high receptor affinity, with the complex binding to LRP1 with greater affinity than either apo-hemopexin or heme alone[7][50]. This preferential high-affinity binding of the hemopexin-heme complex to LRP1 represents an elegant regulatory mechanism ensuring efficient cellular uptake of the heme-loaded form of hemopexin.

The cellular internalization of the hemopexin-heme-LRP1 complex has been directly demonstrated through multiple methodological approaches. Uptake studies of radio-labeled hemopexin-heme complex in LRP/CD91-expressing COS cells and confocal microscopy of the cellular processing of fluorescent hemopexin-heme complex established the ability of LRP/CD91 to mediate hemopexin-heme internalization resulting in cellular heme uptake and lysosomal hemopexin degradation[7][50]. The internalization process involves standard receptor-mediated endocytosis through clathrin-coated pits, followed by transport to early endosomes and then to lysosomes[7][46]. Upon lysosomal degradation of hemopexin, the bound heme is released and becomes available for enzymatic catabolism and iron recovery within the cell.

The functional consequence of hemopexin-heme uptake through the LRP1 pathway includes induction of protective cellular responses. Uptake of hemopexin-heme complex induced LRP/CD91-dependent heme-oxygenase 1 (HO-1) mRNA transcription in cultured monocytes[7][50]. This heme oxygenase-1 induction is mediated through intracellular heme signaling, wherein the released heme interacts with the transcription factor Bach1, leading to its inactivation and release from the HO-1 promoter, permitting NRF2-mediated transcriptional activation[13][16]. The induction of heme oxygenase-1 and its metabolic products (carbon monoxide, biliverdin, and iron) provides potent antioxidant and anti-inflammatory protection at the cellular level.

The LRP1 receptor exhibits extraordinarily broad ligand specificity, serving as a multifunctional receptor for diverse plasma proteins involved in hemostasis, inflammation, and neurobiological processes. Beyond hemopexin-heme complexes, LRP1 serves as a receptor for multiple other ligands including apolipoprotein E, α-2-macroglobulin, tissue plasminogen activator, plasminogen activator inhibitor-1, factor VIII, lactoferrin, and amyloid-beta[49][52]. This broad ligand specificity raises the possibility that in pathological states where multiple ligands are elevated, competition for LRP1-mediated endocytosis may occur, potentially impairing hemopexin-heme clearance. Indeed, impaired heme clearance occurs when CD91 is saturated with its ligands or when hemopexin levels are depleted[5][51].

Heme Catabolism and Iron Recycling

The heme detoxification process is primarily driven by hemopexin through CD91/LRP1-mediated endocytosis in the liver, leading to heme degradation, reutilization, and iron metabolism, with some hemopexin molecules being recycled back into the plasma[5][51]. Upon intracellular delivery of heme to hepatocytes and macrophages, hemopexin releases its bound ligand for internalization and the heme is rapidly catabolized by heme oxygenase enzymes. The primary metabolic pathway for heme involves enzymatic degradation by heme oxygenase (HO), which catalyzes the conversion of heme to biliverdin, carbon monoxide, and iron[5][6][51]. The iron released from heme catabolism is either bound to ferritin for storage or exported from cells to hematopoietic tissues via the iron-transporter ferroportin, where it is reused to support erythropoiesis[5].

This iron recycling process represents a crucial component of iron homeostasis, as the body conserves iron from the continuous catabolism of aging red blood cells. Hemopexin-dependent uptake of extracellular heme leads to the deactivation of Bach1 repression which triggers transcriptional activation of the antioxidant heme oxygenase-1 gene[1]. Furthermore, hemopexin preserves the body's iron through this efficient recycling pathway, ensuring that iron from catabolized hemoproteins is recovered and made available for new hemoglobin synthesis rather than being lost through excretion or deposition in tissues[1]. This iron conservation function becomes especially important during conditions of chronic hemolysis or repeated transfusion where massive amounts of hemoglobin iron must be processed and recycled.

Role in Inflammatory Regulation and Immune Response

Beyond simple heme scavenging, hemopexin plays complex and multifaceted roles in immune regulation that modulate inflammatory responses in both cell-autonomous and non-cell-autonomous mechanisms. Hemopexin and haptoglobin associate with high-density lipoprotein (HDL) and influence the inflammatory properties of HDL, suggesting that hemopexin affects the immunological profile of circulating lipoproteins[1]. Hemopexin can downregulate the angiotensin II Type 1 receptor (AT1-R) in vitro, indicating potential effects on vascular tone and blood pressure regulation through effects on the renin-angiotensin system[1].

The anti-inflammatory effects of hemopexin have been demonstrated in multiple experimental models. Hemopexin downregulates lipopolysaccharide (LPS)-induced production of the inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) in mouse bone marrow-derived macrophages[19]. These anti-inflammatory effects occur through at least two mechanisms: direct heme sequestration preventing heme-mediated toll-like receptor activation, and induction of cytoprotective gene expression programs including heme oxygenase-1 and other antioxidant proteins[5][51]. The heme oxygenase-1 enzyme generates carbon monoxide and biliverdin, both of which possess potent anti-inflammatory properties and suppress pro-inflammatory cytokine production.

Hemopexin functions as an acute-phase protein that is negatively regulated by Th17 cells and serves as a negative regulator of Th17-mediated inflammation. In the experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis, hemopexin content in serum increased and remained high during disease progression[20]. When EAE was induced in hemopexin knockout mice, they developed clinically earlier and exacerbated EAE compared with wild-type mice, associated with a higher amount of CD4+ T cell infiltration[20]. The severe EAE developed by hemopexin-deficient mice could be ascribed to enhanced expansion of Th17 cells accounting for both higher disposition of naive T cells to differentiate toward the Th17 lineage and higher production of Th17-differentiating cytokines IL-6 and IL-23 by antigen-presenting cells[20]. When purified human hemopexin was injected into hemopexin-deficient mice before EAE induction, Th17 expansion and disease severity were comparable with those of wild-type mice, demonstrating that hemopexin's anti-inflammatory effects could be reconstituted by protein supplementation[20].

Hemopexin's anti-inflammatory effects extend to suppression of complement activation pathways. Hemopexin prevented heme-mediated complement activation in both plasma and the kidneys in preclinical models[5]. A recent study revealed that hemopexin could protect factor I activity in vitro, facilitating the degradation of soluble and surface-bound C3b, thus inhibiting complement activation and subsequent vascular and organ injury[5]. These observations suggest that hemopexin acts at multiple points in the complement cascade to limit excessive complement activation that could cause tissue damage.

Central Nervous System Functions and Neuroprotection

Hemopexin is expressed in the central nervous system and plays important roles in neural homeostasis and neurogenic processes. Hemopexin is present in both plasma and cerebrospinal fluid, and is expressed by neurons and glia in the central nervous system[5][51]. Intrathecally produced hemopexin represents another source of hemopexin in cerebrospinal fluid, originating from local synthesis by ependymal cells and neural parenchyma[5][51]. However, hemopexin levels in the cerebrospinal fluid are approximately tenfold lower than those in circulation, suggesting a relatively low capacity for heme binding in the brain, which can become easily overwhelmed in pathological states[5][51].

The neuroprotective functions of hemopexin have been demonstrated in multiple disease contexts. An ex vivo study supported the neuroprotective effects of hemopexin, as it protects neurons and glial cells from blood-related injuries through antioxidation and downregulation of heme oxygenase-1 and caspase-3 expression[5][51]. Preclinical research indicated that higher levels of hemopexin in the brain improve outcomes after intracerebral hemorrhage in mouse models[5][51]. Elevated local hemopexin levels were associated with smaller lesion volumes, reduced perihematomal tissue injury, and trends toward decreased hematoma volumes[5][51]. Additionally, mice with higher hemopexin levels experienced no significant changes in brain iron levels and heme oxygenase-1 expression but exhibited increased microglial activation and decreased astrocytic activation and lipid peroxidation, suggesting the potential synergy of central and peripheral heme clearance[5][51].

Beyond heme scavenging, hemopexin plays an unexpected role in neural stem cell biology and adult neurogenesis. Hemopexin deletion leads to neurogenic abnormalities in the subventricular zone/olfactory bulb pathway[26]. The lateral ventricle is enlarged in hemopexin-deficient mice, and more apoptosis is observed in doublecortin (Dcx)+ neuroblasts[26]. Lineage differentiation of neural stem cells was inhibited in the subventricular zone of hemopexin-deficient mice, with more stem cells remaining in an undifferentiated, GFAP+ radial glia-like cell stage[26]. Moreover, hemopexin deletion resulted in impaired neuroblast migration in the rostral migratory stream[26]. Exogenous hemopexin protein inhibited apoptosis and promoted the migration and differentiation of cultured neural stem cells[26]. Immunohistochemical analysis demonstrated that hemopexin deletion reduced the number of interneurons in the olfactory bulb[26]. These findings reveal a previously unknown function for hemopexin in the central nervous system, operating as a regulatory factor during adult neurogenesis through mechanisms that appear to extend beyond simple heme detoxification.

Role in Brain Iron Homeostasis

Hemopexin plays an important role in controlling brain iron distribution and iron-related processes in neural tissue. Hemopexin-null mice demonstrate altered iron distribution in brain with increased iron accumulation in specific regions. Analysis of Perl's-stained serial sections encompassing the basal ganglia and thalamus revealed increased numbers of iron-loaded cells in hemopexin-null mice compared to age-matched wild-type controls[21]. Prominently affected areas included the globus pallidus and the caudate-putamen nucleus, with counts of Perl's-positive cells showing approximately twofold greater iron loading in hemopexin-null mice[21].

Consistent with increased iron deposits and inadequate ferritin expression, malondialdehyde levels and Cu–Zn superoxide dismutase-1 expression were higher in the brain of hemopexin-null mice than in wild-type controls[21]. These data demonstrate that hemopexin plays an important role in controlling iron distribution within brain, thus suggesting its involvement in iron-related neurodegenerative diseases[21]. The increased oxidative stress markers and altered antioxidant enzyme expression in hemopexin-deficient brains indicate that hemopexin deficiency leads to iron-dependent oxidative stress in neural tissue.

However, the relationship between hemopexin and Alzheimer's disease pathology appears complex and potentially context-dependent. Low cerebrospinal fluid levels of hemopexin are associated with increased Alzheimer's pathology, hippocampal hypometabolism, and cognitive decline in some studies[29]. In contrast, other studies have reported that higher plasma hemopexin levels are associated with progression of Alzheimer's disease pathology and decline in cognitive score[47]. Proteomics studies have demonstrated increased plasma and cerebrospinal fluid hemopexin in Alzheimer's disease patients compared to cognitively normal subjects, suggesting impaired compensation in neurodegeneration[47]. These apparently contradictory findings may reflect the complex balance between protective effects of hemopexin-mediated heme scavenging and potentially harmful effects of hemopexin-mediated disruption of normal iron homeostasis in the context of amyloid and tau pathology.

Disease-Specific Roles and Therapeutic Potential

Sickle Cell Disease and Vaso-Occlusion

In sickle cell disease, hemopexin plays a critical protective role against heme-mediated vascular complications. Hemolysis releases free hemoglobin and hemoglobin-containing microparticles into the vasculature that upon oxidation to methemoglobin free heme from the globin, which in turn can promote oxidative stress and activate toll-like receptor 4 (TLR4) signaling[37]. In mouse models of sickle cell disease, unless hemopexin is present or replenished, heme causes endothelial cells to present surface adhesion molecules leading to stasis and vaso-occlusion in part via toll-like receptor-4 activation and pulmonary endothelia to produce neutrophil extracellular traps[19]. Sickle cell disease patients have low serum hemopexin levels likely due to chronic hemolysis leading to increased hemopexin catabolism with insufficient compensatory increase in synthesis[37].

Acute studies have shown hemopexin infusion prior to a heme challenge protects sickle mice from vaso-occlusion and developing acute pulmonary injury[37]. Chronic hemopexin infusion therapy modified heme toxicity to endothelium[37]. HPX-deficient sickle mice had 34% ± 3% microvascular stasis at 1 hour post-heme challenge and 24% ± 2% at 4 hours, significantly greater than hemopexin-replete sickle mice which had 21% ± 5% and 13% ± 8% at 1 and 4 hours respectively[37].

Gene therapy studies have demonstrated that hepatic overexpression of hemopexin in transgenic sickle mice via Sleeping Beauty transposon-mediated gene therapy markedly increases nuclear Nrf2 expression in the livers of sickle mice, presumably by promoting delivery of heme to the liver and activating the Keap1-Nrf2 axis[37]. In addition, hepatic heme oxygenase-1 activity and protein and CD91 protein were increased in sickle mice overexpressing hemopexin and NF-κB activation was markedly decreased as assessed by nuclear phospho-p65-NF-κB expression[37]. These findings demonstrate that supplementing hemopexin levels in transgenic sickle mice via gene therapy activates the antioxidant Nrf2 axis and ameliorates inflammation and vaso-occlusion[37].

Plasma-derived hemopexin has demonstrated bioavailability and therapeutic efficacy in preclinical models of sickle cell disease. Hemopexin administered intravenously prevented or relieved vascular stasis induced by free hemoglobin and by hypoxia-reoxygenation in a dose-dependent manner[40]. Plasma-derived hemopexin inhibited heme-mediated cellular externalization of P-selectin and von Willebrand factor, and expression of IL-8, VCAM-1, and heme oxygenase-1 in cultured endothelial cells in a dose-responsive manner[40]. Repeated intravenous administration of hemopexin was well tolerated in rats and non-human primates with no adverse findings attributable to human hemopexin[40]. Hemopexin had a half-life in wild-type mice, rats, and non-human primates of 80–102 hours, whereas a reduced half-life of hemopexin in Townes sickle cell disease mice was observed (approximately 7 hours) due to ongoing hemolysis and target-mediated drug disposition[40][59]. These pharmacokinetic data have led to a Phase 1 clinical trial of hemopexin in adults with sickle cell disease, which is currently ongoing[40].

Sepsis and Critical Illness

Hemopexin plays important protective roles in sepsis and other critical illnesses involving hemolytic stress and infection-induced inflammation. Elevated heme levels, a consequence of hemolysis, are strongly associated with increased susceptibility to bacterial infections and adverse sepsis outcomes, particularly in older populations[38]. Mean plasma hemopexin levels are increased above baseline in mouse models of endotoxemia, burn wound infection, and peritonitis-induced sepsis[41]. Several lines of evidence have suggested that hemopexin could be beneficial in settings where infection and free heme coexist[41]. First, hemopexin decreases the synergistic production of TNF and IL-6 from macrophages exposed to heme or hemoglobin together with lipopolysaccharide, Escherichia coli, Staphylococcus aureus, or HMGB1[41]. Second, hemopexin has been protective in mouse models of sepsis[41]. Third, elevated cell-free plasma hemoglobin or decreased plasma hemopexin is associated with increased mortality in sepsis[41].

In a sepsis model using cecal ligation and puncture, elevated heme levels correlate with Kupffer cell loss, increased bacterial burden, and heightened mortality[38]. Mechanistically, heme activates phospholipase C gamma (PLC-γ), facilitating the translocation of cleaved gasdermin D to mitochondria, resulting in mitochondrial dysfunction and release of mitochondrial DNA during bacterial infection[38]. This mitochondrial damage amplifies PANoptosis (a form of cell death integrating pyroptosis, apoptosis, and necroptosis) and triggers the cGAS-STING signaling pathway, further driving immune senescence[38].

Hemopexin treatment significantly reduces mitochondrial damage, cell death, and senescence caused by heme and bacterial infection[38]. Hemopexin effectively mitigates sepsis-induced Kupffer cell death and senescence, enhances bacterial clearance, and improves survival outcomes in both young and aged mice[38]. Notably, aging is associated with reduced hemopexin levels, which may contribute to increased heme-mediated immune dysfunction and potentially increased susceptibility to sepsis in elderly populations[38].

Plasma hemopexin concentrations are markedly decreased or virtually undetectable in some patients with sepsis and acute respiratory distress syndrome, some patients with severe burns, and most premature infants[41]. These results support the concept that there is a subset of patients in each population who might benefit from hemopexin repletion[41]. However, IL-6 levels were negatively correlated with hemopexin levels in mouse models, possibly due to hepatic dysfunction or the increased consumption of hemopexin by binding to increased free heme that outstripped production[41].

Anthracycline Cardiotoxicity

Circulating hemopexin modulates anthracycline-induced cardiotoxicity, representing an unexpected cardioprotective mechanism. An increase in hemopexin at 3 months after anthracycline initiation was associated with cardiac toxicity as assessed by echocardiography[39]. However, preclinical data demonstrate that hemopexin deficiency exacerbates doxorubicin-induced cardiac dysfunction, with hemopexin deficiency exacerbating increased lipid peroxidation and dichlorofluorescein (DCF) fluorescence in the heart with or without doxorubicin treatment[39]. Hemopexin administration to wild-type mice treated with doxorubicin improved cardiac function[39].

This study supports a role for hemopexin induction as a cardioprotective mechanism activated in the setting of doxorubicin-induced chronic cardiomyopathy[39]. Although plasma hemopexin levels in patients were associated with increased cardiac toxicity, the preclinical data suggest that higher levels of hemopexin in patients treated with anthracyclines should be physiologically beneficial and cardioprotective[39]. The hypothesis is that circulating hemopexin increased in both patients and mice in response to anthracycline-induced cardiac dysfunction, representing an endogenous adaptive response to mitigate cardiotoxicity[39]. Both baseline levels of hemopexin and changes in hemopexin over time were associated with early cardiac toxicity, suggesting that hemopexin may serve as a useful biomarker for anthracycline cardiotoxicity[39].

Hemorrhagic and Traumatic Brain Injury

The role of hemopexin in traumatic brain injury and intracerebral hemorrhage has been explored in preclinical models. Deletion of the hemopexin gene can aggravate brain injury followed by stroma-free hemoglobin-induced intracerebral hemorrhage[1]. High hemopexin levels in cerebrospinal fluid are associated with poor outcome after subarachnoid hemorrhage in some studies, although the mechanism underlying this apparent paradoxical relationship remains to be elucidated[1]. A possible explanation is that when the level of hemopexin in cerebrospinal fluid is excessively high, it may become deleterious as it impedes the efflux of heme due to its high heme affinity, resulting in intracellular heme/iron overload, which can be toxic to neurons and glia[51].

In a mouse model of intracerebral hemorrhage, endogenous low-density lipoprotein receptor-related protein-1 and hemopexin were increased in ipsilateral brain after intracerebral hemorrhage, accompanied by increased hemoglobin levels, brain water content, blood–brain barrier permeability and neurological deficits[49]. Exogenous recombinant LRP1 increases hemopexin-heme scavenging and reduces oxidative stress and neuronal apoptosis after intracerebral hemorrhage, with these protective effects tended to be reversed by siRNA-mediated knockdown of LRP1[49]. These results demonstrate that LRP1 is involved in heme scavenging and blood-brain barrier protection in adjacent hematoma brain tissue after intracerebral hemorrhage[49].

Iron Homeostasis and Metabolic Functions

Hemopexin contributes to whole-body iron homeostasis through its role in heme-iron recovery and redistribution. Hemopexin binds heme and transports it to the liver for breakdown and iron recovery, after which the free hemopexin returns to the circulation[3][6]. This efficient recycling system ensures that iron from degraded hemoproteins is conserved and made available for new hemoglobin and other heme-containing protein synthesis. Impaired heme clearance occurs when CD91 is saturated with its ligands or when hemopexin levels are depleted, compromising the body's ability to manage heme-derived iron during periods of hemolytic stress[5][51].

In the duodenum, hemopexin influences iron uptake and handling. Hemopexin-null mice showed elevated iron deposits in enterocytes, associated with higher duodenal high-chain-ferritin levels and a significant increase in duodenal heme oxygenase activity[24]. This suggests that hemopexin regulates the amount of heme available for absorption in the intestine, thereby controlling intestinal iron uptake from dietary heme sources. The increased heme oxygenase activity in hemopexin-deficient duodenum suggests compensatory induction of heme-catabolizing enzymes in response to elevated heme levels, leading to increased iron uptake from enhanced local heme catabolism.

Pathophysiological Context and Context-Dependent Functions

While hemopexin generally functions in a protective capacity, emerging evidence indicates that hemopexin can exert harmful effects under certain pathological conditions, particularly when hemopexin levels are elevated in specific tissue compartments or disease contexts. A study revealed that skeletal muscle atrophy-induced hemopexin accelerates the onset of memory impairment in a mouse model of Alzheimer's disease[44]. Continuous intracerebroventricular infusion of recombinant hemopexin for 2 weeks induced memory deficits in young 5XFAD mice, with lipocalin-2 (a neuroinflammatory factor) increased in the hippocampus in hemopexin-infused 5XFAD mice compared to control mice[44]. The hypothesis emerging from this research is that skeletal muscle atrophy elicits cognitive impairment through the secretion of hemopexin that travels to the brain and exerts detrimental effects on neural function[44].

This context-dependent dual role of hemopexin reflects the complexity of heme biology in disease states. While hemopexin's heme-scavenging function is generally protective against heme toxicity and oxidative damage, excessive hemopexin in specific tissue compartments or under certain pathological conditions may impair local iron homeostasis or generate unwanted inflammatory responses. The mechanisms underlying these context-dependent effects remain incompletely understood but likely involve alterations in local iron metabolism, changes in the balance of protective versus toxic heme metabolites (such as carbon monoxide and biliverdin versus oxidative products), and shifts in the tissue microenvironment that alter hemopexin's immunological effects.

Structural Family and Related Proteins

Hemopexin belongs to the hemopexin family of evolutionarily related proteins characterized by hemopexin-like repeating domains. Hemopexin-like repeats occur in vitronectin and some matrix metalloproteinases family members (matrixins)[31]. The hemopexin-like domains facilitate binding to a variety of molecules and proteins; for example, the hemopexin repeats of some matrixins bind tissue inhibitor of metallopeptidases (TIMPs)[31]. The hemopexin domain in matrix metalloproteinases is located in the C-terminal section of the protein and facilitates binding to inhibitory proteins and cellular receptors, including LRP1[31][52].

In some teleost fish species, duplicate copies of the mammalian hemopexin ortholog exist, including a warm temperature acclimation-related protein (WAP65)[45][48]. These fish hemopexin orthologs likely perform similar heme-binding functions as mammalian hemopexin but may have acquired additional functions related to temperature acclimation. The conservation of hemopexin structure and function across vertebrate species indicates that heme scavenging represents an ancient and fundamental physiological requirement for organisms utilizing heme as a prosthetic group for oxygen transport and metabolism.

Synthesis, Molecular Characteristics, and Quantification

Hemopexin is a single-chain plasma glycoprotein with a molecular weight of approximately 60 kilodaltons (or 57 kilodaltons in some literature references)[5][51][54]. The protein is composed of approximately 440 amino acid residues and exhibits extensive post-translational modifications including both N-linked and O-linked glycosylation[32][35]. The high carbohydrate content of hemopexin (approximately 20% by mass) contributes to its solubility and may influence its binding properties and receptor interactions[32][35]. The glycosylation of hemopexin includes 12 sites of glycosylation overall: 5 N-linked glycosylation sites and 6 O-linked glycosylation sites (accounting for approximately 226 N-linked glycans and 9 O-linked glycans respectively)[3].

The native fluorescence properties of hemopexin reflect its tryptophan content and the conformational changes that occur upon heme binding. The hemopexin molecule contains 18 tryptophan residues arranged in four distinctive clusters, each cluster containing three to four tryptophan residues separated by zero to twelve intervening amino acids[32][35]. Both heme and metal-free porphyrin binding effectively quench the tryptophan fluorescence of hemopexin, observations that do not necessarily indicate direct participation of tryptophan in the heme-binding site but imply that tryptophan-tryptophan interactions are affected when heme is bound by hemopexin[32][35]. The intrinsic fluorescence of hemopexin can therefore be exploited as an analytical tool for detecting and quantifying heme binding.

Conclusion and Future Directions

Hemopexin represents a multifunctional plasma glycoprotein that serves as the highest-affinity heme-binding protein known, with extraordinary binding affinity that enables effective scavenging and detoxification of free heme released from hemoproteins under conditions of hemolysis, hemorrhage, and cellular stress[1][14][17][51]. The primary function of hemopexin—the sequestration and transport of free heme to hepatocytes and macrophages for catabolism and iron recovery—represents a critical protective mechanism that prevents the oxidative damage, inflammatory activation, and cellular toxicity that would otherwise result from circulating free heme[1][5][51]. The molecular basis for this extraordinary binding affinity resides in the unique structural organization of two similar four-bladed β-propeller domains connected by a flexible hinge region containing critical histidine residues that coordinate the heme iron[14][17].

Beyond classical heme detoxification, emerging evidence has expanded understanding of hemopexin function to encompass multiple biological processes including immune regulation, anti-inflammatory signaling, neural stem cell biology, brain iron homeostasis, vascular function, and cardiac metabolic adaptation[1][5][20][26][39][51]. The identification of multiple hemopexin receptor systems including the well-characterized LRP1/CD91 receptor and alternative transferrin receptor-mediated pathways indicates that hemopexin functions through tissue-specific endocytic mechanisms adapted to the particular physiological needs of different cell types and tissues[7][8][43][50]. The therapeutic potential of hemopexin supplementation in hemolytic diseases including sickle cell disease, transfusion-induced hemolysis, and sepsis has been demonstrated in preclinical models and has led to ongoing clinical trials[37][40].

However, context-dependent and potentially harmful effects of hemopexin in specific disease states—such as accelerated cognitive decline in Alzheimer's disease, poor prognosis after subarachnoid hemorrhage, and associations with cardiac toxicity following anthracycline therapy—indicate that the biological effects of hemopexin are not uniformly protective[39][44][51]. Future research must clarify the mechanisms underlying these context-dependent effects, define the tissue-specific and pathological conditions in which hemopexin supplementation would be beneficial versus harmful, and develop strategies to optimize hemopexin-based therapeutic approaches. The multifunctional nature of hemopexin as both a protective heme scavenger and a signaling molecule capable of influencing gene expression, immune function, and tissue development represents a compelling target for therapeutic intervention in multiple disease contexts characterized by hemolytic stress, oxidative injury, and dysregulated heme metabolism.

Citations

1. https://en.wikipedia.org/wiki/Hemopexin
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC8998376/
3. https://pubchem.ncbi.nlm.nih.gov/protein/P02790
4. https://www.ncbi.nlm.nih.gov/gene/3263
5. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1274333/full
6. https://www.reactome.org/content/schema/instance/browser/uniprot:P02790
7. https://pubmed.ncbi.nlm.nih.gov/15947085/
8. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2025.1613917/full
9. https://ashpublications.org/blood/article/106/7/2225/21652/Handling-heme
10. https://reactome.org/content/detail/R-HSA-2168897
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC10653390/
12. https://journals.sagepub.com/doi/abs/10.1177/15353702221139185
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC129038/
14. https://www.nature.com/articles/nsb1099_926
15. https://www.semanticscholar.org/paper/f878445a667a3bcba208c3f9911ba87da30d1cfc
16. https://academic.oup.com/nar/article/35/21/7074/2375687
17. https://pubmed.ncbi.nlm.nih.gov/10504726/
18. https://pubmed.ncbi.nlm.nih.gov/7681064/
19. https://pmc.ncbi.nlm.nih.gov/articles/PMC4485156/
20. https://pubmed.ncbi.nlm.nih.gov/24154625/
21. https://pmc.ncbi.nlm.nih.gov/articles/PMC4496126/
22. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2014.00415/full
23. https://pubmed.ncbi.nlm.nih.gov/34298052/
24. https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0068146
25. https://www.nature.com/articles/cmi201597
26. https://www.nature.com/articles/s41419-018-0328-0
27. https://pubmed.ncbi.nlm.nih.gov/7857266/
28. https://pmc.ncbi.nlm.nih.gov/articles/PMC7775585/
29. https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.202400863RR
30. https://en.wikipedia.org/wiki/Hemopexin_family
31. https://www.pnas.org/doi/pdf/10.1073/pnas.81.7.2021
32. https://pmc.ncbi.nlm.nih.gov/articles/PMC6925827/
33. https://www.ncbi.nlm.nih.gov/Structure/cdd/cl02471
34. https://pmc.ncbi.nlm.nih.gov/articles/PMC345428/
35. https://pubmed.ncbi.nlm.nih.gov/8096/
36. https://ashpublications.org/blood/article/126/23/412/136085/Hemopexin-Gene-Therapy-Inhibits-Inflammation-and
37. https://www.nature.com/articles/s41419-025-07637-6
38. https://pmc.ncbi.nlm.nih.gov/articles/PMC9788780/
39. https://pubmed.ncbi.nlm.nih.gov/35160081/
40. https://pmc.ncbi.nlm.nih.gov/articles/PMC4424824/
41. https://database.clin-star.org/display/project-5R01HL16317203
42. https://pmc.ncbi.nlm.nih.gov/articles/PMC8718090/
43. https://pubmed.ncbi.nlm.nih.gov/24344252/
44. https://pubmed.ncbi.nlm.nih.gov/1964416/
45. https://pmc.ncbi.nlm.nih.gov/articles/PMC7285604/
46. https://academic.oup.com/jhered/article/105/2/237/791325
47. https://pmc.ncbi.nlm.nih.gov/articles/PMC5453452/
48. https://pubs.acs.org/doi/10.1021/acs.biochem.3c00705
49. https://pubmed.ncbi.nlm.nih.gov/30219641/
50. https://pubmed.ncbi.nlm.nih.gov/19650691/
51. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2015.00187/full
52. https://pmc.ncbi.nlm.nih.gov/articles/PMC4211382/
53. https://pmc.ncbi.nlm.nih.gov/articles/PMC2880807/
54. https://pmc.ncbi.nlm.nih.gov/articles/PMC8836474/
55. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2014.00034/full